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ABSTRACT
The activation of the transcription factor NF-kB and its 
inhibition by I-kB has been the subject of much research. 
However, there are many questions which remain unanswered 
regarding the functional properties of, and relationship 
between, the factor and the inhibitor. In this study, 
antibodies directed against the protein components of NF-kB 
and I-kB have been produced and used as tools to determine 
the subcellular localisation of both proteins in different 
cell lines both before and after activation with various 
agents. In particular the production and characterisation of 
monoclonal antibody 3B6 will be described. This antibody was 
raised against the p50 subunit of NF-kB and recognises an 
epitope contained within the nuclear localisation signal of 
the protein. Polyclonal antisera raised against p50 and I-kB 
were used in Western blots and immunofluorescence 
experiments and show changes in the localisation of NF-kB 
subunits and I-kB following activation of cells for various 
times.
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INTRODUCTION
The transcription factor NF-kB (nuclear factor kappa B) is 
a transcription factor which, on activation, induces 
transcription of a variety of genes including the kappa Ig 
light chain gene, many cytokines, cell surface receptors and 
some viruses, including HIV-1, NF-kB belongs to a family of 
proteins which are controlled by a family of inhibitor 
proteins characterised by the possession of "ankyrin 
repeats”. The factor itself, its subunits, and the inhibitor 
family will be discussed in detail below.
Identification of NF-kB
Nuclear factor kappa B was first identified in 1986 (1) as a 
factor which interacts with a sequence in the large intron 
of the k light chain gene, identified as a B cell specific 
enhancer element in the Ig kappa chain gene (2,3). Binding 
of this factor to the enhancer DNA could be competed for by 
addition of the complete k enhancer or the SV40 enhancer. 
This result suggested that the binding site for NF-kB could 
be an 11 nucleotide sequence - GGGGACTTTCC - common to both 
enhancers. This prediction was confirmed by méthylation 
interference analysis of the nucleoprotein complex. 
Analysis of factor binding in nuclear extracts from a 
variety of cell lines showed NF-kB to be found only in cells 
of the B lymphoid lineage which had differentiated to mature 
B cells or plasma cells : the factor was not found in pre B 
cells or T cells.
If NF-kB was critical for activation of the k enhancer, it
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would have to be inducible in pre B cell lines following 
treatment with an appropriate stimulus. The cell line 70Z/3 
has the phenotype of a pre B cell, since it synthesises 
cytoplasmic u chain but no light chain (4,5). The k chain 
gene in these cells is functionally rearranged but is not 
transcriptionally active (6,7) unless cells are treated with 
bacterial lipopolysaccharide (LPS) which results in 
initiation of k transcription, synthesis of k chain protein 
and appearance of IgM on the cell surface. This treatment 
with LPS also induces a DNAase I-hypersensitive site 
associated with the k enhancer and on this basis it was 
suggested that k transcription is due to activation of the k 
enhancer (8).
Studies using this 70Z/3 line and another pre B cell line, 
PD (k chain in the process of rearrangement), showed that 
NF-kB , activity in these cells was inducible by LPS as 
detected by electrophoretic mobility shift assay (EMSA) (9). 
The phorbol ester phorbol 12-myristyl 13-acetate (PMA) was 
also shown to induce NF-kB activity in 70Z/3 cells but the 
time course of activation by the two agents was different. 
Treatment with LPS results in detection of NF-kB after 0.5 
hour stimulation, with NF-kB levels increasing until 2 hours 
after stimulation when the level plateaus out, whereas in 
PMA stimulated cells the maximum detection of NF-kB is at 
0.5 hours after stimulation, remaining constant for 2 - 3
hours then rapidly decreasing until non detectable 8 hours 
after stimulation. This rapid decline of NF-kB was
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postulated to be due to decreased activity of endogenous 
protein kinase C (PKC) due to prolonged exposure of the 
cells to phorbol esters, suggesting that PKC activity is 
necessary to maintain NF-kB activity. The faster response to 
PMA than LPS could be explained by the direct action of PMA 
on PKC, whereas LPS activates phospholipase C (PLC) which in 
turn generates inositol triphosphate (IP^) and diacyl 
glycerol (DAG), which in turn activate PKC (10).
Treatment of 70Z/3 B cells with inhibitors of translation 
(cycloheximide or anisomysin) for 10 minutes followed by 
stimulation with LPS also induced expression of the k chain 
gene, as did treatment with cycloheximide alone (11), 
Further analysis of cells treated with cycloheximide alone, 
anisomysin alone or cycloheximide plus LPS showed that such 
treatments also induced NF-kB and that treatment with both 
agents results in a superinduction of the factor (9). These 
results show that induction of NF-kB in 70Z/3 cells does not 
require new protein synthesis and so must involve post 
translational modification of an existing protein.
Further agents have been shown to induce NF-kB activity in 
the 70Z/3 line. These include interleukin 1 (Il-l), tumour 
necrosis factor <x (TNFx) and virus infection - all of which 
stimulated transcription of the k locus thus reinforcing the 
correlation between NF-kB induction and k light chain gene 
expression (9,12,13,14). Confirmation of this correlation 
was further provided by direct demonstration of chromatin 
changes and occupancy of the NF-kB site in the nuclei of LPS
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treated 70Z/3 cells (15,16). Additional studies have shown 
that genetically altered 70Z/3 cells, which have defective k 
gene expession following LPS treatment, are also abnormal in 
their ability to activate NF-kB (18,19).
As previously mentioned, initial studies on pre B cells, non 
B cells and T cells failed to detect NF-kB activity but 
following the reports of the inducibility of NF-kB in pre B 
cells, further studies were done to determine whether NF-kB 
is also inducible in other cells such as T cells and 
nonlymphoid cells. The human T leukaemia cell line, Jurkat, 
had previously been shown to produce interleukin2 (11-2) on 
stimulation with phytohaemagglutinin (PHA) plus PMA (20,21). 
Extracts were made from these cells stimulated with either 
or both agents, and analysed for NF-kB activity. NF-kB was 
induced in all cases with the costimulated cells exhibiting 
a higher level of activation. In PMA treated Hela cell 
extracts NF-kB activity was also induced (9).
This supported the idea that NF-kB must exist as an inactive 
precursor, or complexed with an inhibitor molecule, with 
certain stimuli resulting in release of active NF-kB after 
modification of the precursor or the protein-inhibitor 
complex. To investigate the state of NF-kB in unstimulated 
cells nuclear and cytosolic extracts from unstimulated or 
13-0-tetrodecanoyl 12-phorbolacetate (TPA) stimulated 70Z/3 
cells were examined for NF-kB binding activity (22). Both 
nuclear and cytosolic extracts from unstimulated cells 
exhibited very little kB specific binding activity, but
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following treatment with TPA for 30 minutes the nuclear 
NF-kB activity increased dramatically with no increase in 
activity seen in the cytosolic fraction. The extracts from 
unstimulated cells were then subjected to dénaturation, 
fractionation and renaturation - after which the majority of 
in vitro NF-kB activity was detected in the cytosolic 
fraction, suggesting that the factor may be bound to an 
inhibitor. Treatment of the cytosolic fraction with 
dissociating agents resulted in activation of the cytosolic 
kB binding activity. In experiments using equal cell 
equivalents of protein the amount of cytosolic NF-kB in 
unstimulated 70Z/3 cells was shown to be the same as the 
amount of nuclear NF-kB in stimulated cells (22).. The same 
studies using Hela cells also showed the presence of 
inactive cytosolic NF-kB, with the total cellular NF-kB 
activity remaining constant before and after TPA activation, 
although activation by TPA in Hela cells is less complete. 
The transcription factor NF-kB has now been found in 
virtually all cell types examined, and it has been shown 
that its activation involves some form of post translational 
modification of a pre-existing cytoplasmic form.
Purification of NF-kB
Following the identification and partial characterisation of 
NF-kB, DNA affinity purification was carried out using 
double stranded multimers of the previously identified 
binding site 5*GGGACTTTCC 3'. Different groups purified the
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factor from different sources - namely human cell lines 
(23,24), human placenta (25) and rabbit lung (26).
NF-kB was purified from two human cell lines : Namalwa cells 
(a human Burkitt lymphoma cell line) and Hela cells. In both 
cases a DNA binding activity of about 50kD was isolated by 
affinity chromatography - though nuclear extracts from 
Namalwa cells (23) and deoxycholate treated cystolic 
extracts from Hela cells (24) were used. The purification 
from Hela cell extracts also yielded a 65kD protein which 
did not bind DNA.
In the purification from human placenta a much more 
stringent washing procedure using chloroquine and potassium 
chloride (KCl) was employed (25) to reduce the purification 
to a much more cost effective one step process, rather than 
the multiple rounds of affinity chromatography that were 
required previously. Again the DNA binding activity of 
NF-kB was isolated.
The DNA binding p50 subunit of NF-kB was also purified from 
rabbit lungs (26). In this case the purification process was 
modified from multiple rounds of affinity chromatography by 
use of KCl elutions and a negative selection step using a 
mutant kB site. Using this procedure a high yield of good 
purity NF-kB was obtained - consisting of a 50kD and a 65kD 
fraction which displayed the characteristics of the p50 and 
p65 NF-kB subunits.
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Cloning and Characterisation of the p50 Subunit
From this preparation the p50 was sequenced and then cloned. 
Sequencing of tryptic peptides of p50 purified by high 
performance liquid chromatography (HPLC) yielded a primary 
protein sequence of 166 amino acids. (26).
Polymerase chain reaction (PCR) amplification using primers 
from 2 of the tryptic peptides and a template of cDNA from 
total rabbit spleen and lung was performed. Screening of a 
mouse cDNA library identified 5 clones each containing 
inserts of about 4.0kb which were identical by restriction 
mapping. Sequencing of one of the clones showed a long open 
reading frame which encodes a 107kD protein. Presumably this 
is then processed to yield the 50kD p50, and a glycine rich 
region around amino acid 400 may be a cleavage site.
A database search looking for homologies with the predicted 
amino acid sequence for p50 showed a remarkable similarity 
to C-rel ( a turkey proto-oncogene) (27), v-rel (the viral 
oncogenic counterpart of C-rel) (28) and dorsal (a maternal 
effect gene in Drosophila) (29). See Figure 1.
Figure 1.
rel homology PKA gly spacer Ankyrin repeatsDNA binding RRKS T
limerisatlon_____X x _T[
QRKRQK Nuc loc.
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Common to all rel related proteins is the property of 
selective nucleo/cytoplasmic distribution in response to 
different factors. A nuclear localisation signal (NLS) is 
found between amino acids 358-3 63 (30). All the proteins 
also have a potential site for phosphorylation by protein 
kinase A (PKA) (29) although its position is unknown.
Also described in the literature around this time were two 
other factors which bound to the same 10 base pair sequence 
as NF-kB. These factors were known as (Enhancer Binding 
Protein 1) EBPl (31) and KBFl (32). EBPl was shown to bind 
to an NF-kB site in the HIV-1 enhancer, and DNAase 
footprinting showed that in fact both NF-kB binding sites in 
the enhancer could be occupied by EBPl (33). DNA protein 
complexes formed by inducible NF-kB from Jurkat cells and 
target DNA have the same mobility as those formed by EBPl 
and target DNA, and binding of both factors can be competed 
out by the same double stranded oligonucleotides. Further 
evidence also supported the notion that EBPl is in fact the 
activated form of NF-kB (p50) and it is now accepted as such 
(34,35). Cloning of KBFl purified from Hela cells showed 
that KBFl cDNA encodes a 105kD protein, with KBFl located in 
the N terminal region (32). Strong homology with rel
family proteins was also noted with the DNA binding domain 
and a dimérisation domain being located in the homologous 
region. The C terminal region was shown to contain eight 
repeats of 33 amino acids which are similar to those found 
in the human erythrocyte ankyrin protein. KBFl was shown to
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be identical to p50 of NF-kB by molecular weight, 
protein-DNA complex mobility in a band shift assay, binding 
site affinity, DNA contact points, association with p65, 
cross reactivity with antisera and partial amino acid 
sequence (32). Again, KBFl is now accepted as one and the 
same as NF-kB p50 (34,35).
Another group also purified p50 from another human cell 
line, HL60 (36). The cells were activated with TNFx, and 
nuclear extracts prepared then purified using the protocol 
described briefly above (23). The purest fraction obtained 
gave rise to two protein species - one of 51kD and one of 
65kD - and these showed all the characteristics of p50 and 
p65 respectively. The p51 fraction was then sequenced, again 
by HPLC of tryptic peptides and oligonucleotides prepared 
from peptide sequences were used to screen a human .cDNA 
library. Once again, an open reading frame encoding a 105kD 
protein was isolated, with the peptides obtained from p50 
all mapping to the N terminus - thus suggesting this to 
encode p51. Compared with the KBFl/p50 sequence (32), there 
is one codon missing from this sequence which is explained 
as a possible allelic difference (36). The cloned p51 was 
also found to have a high level of homology with rel family 
proteins.
Fragments of the cloned cDNA's were used to probe cells for 
the 3-8kb transcript before and after stimulation with 
either TNFx or phorbol ester. Following activation by either 
agent, the transcript levels were greatly increased in both
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HL60 and Hela cells suggesting that a more long term 
activation of NF-kB may involve induction of NF-kB mRNA 
(36) .
Cloning of p65.
In the process of purifying p50, some groups also purified a 
65kD protein, known as p65 (24,26,36). Following the
successful cloning of p50 protein purified from rabbit lung 
(26), p65 was cloned in a similar manner (37) using primers 
from rabbit derived peptides to PCR mRNA from both rabbit 
lung and a murine pre B cell line 2206. The rabbit and 
murine clones obtained shared more than 97% amino acid 
homology, and the murine PCR insert was then used to probe a 
2206 cDNA library.
The ■ open reading frame obtained encodes a 60.2kD protein 
which encompasses the sequences of all the peptides obtained 
from purified p65. The predicted sequence, like p50, shows 
strong homology to members of the rel family of proteins
with greatest similarity to c-rel. The carboxyl terminus of 
c-rel has a transcription activation domain (38,39), which 
shares charge distribution similarity with p65. The role of 
this region will be discussed in more detail later.
The cloned p65 subunit satisfied several criteria to be 
recognised as NF-kB p65. Peptides from affinity purified
size separated NF-kB p65 were used to isolate cDNA which
included peptides not used in the cloning. The protein 
obtained by in vitro translation runs at about 65kD and 
forms a DNA binding complex with p50 - the DNA binding of
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which is inhibited by I-kB. Finally, the expected broad 
tissue distribution of the p65 gene is confirmed by Northern 
blot analysis.
The Structure and Function of p50 and p65.
Structure
As already described briefly, cloning of both p50 and p65 
showed that both proteins share homology with members of the 
rel family of proteins (26,32,38). This homology is 
contained in a 300 amino acid sequence which functions as a 
DNA binding and dimerization domain and also contains 
sequences responsible for inhibitor binding and nuclear 
localisation. For simplicity, this region will be referred 
to as the rel homology domain (RHD). Sequences which lie to 
the C terminus of the RHD are unrelated in these proteins
(40).
The RHD is unusual as a DNA binding and dimerization domain 
in that it requires the entire 300 amino acids to function
(41) - this is unusually long. Another unusual feature is 
the lack of DNA binding motif normally seen in the 
equivalent domain of other transcription factors such as 
leucine zipper or helix-loop-helix. It has been shown that 
members of this family can form both homodimers and 
heterodimers.
Further dissection of the RHD of p50 has been done using 
deletion mutants created by restriction enzyme digestion of 
full length cDNA (26,32,42). These studies showed that DNA 
binding, detected by band shift assay, was abolished in any
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protein longer than 670 amino acids from the N terminus. 
Internal deletions mapped the DNA binding domain to amino 
acids 19 to 399, with the C terminal region of the precursor 
lOSkD protein preventing DNA binding. Co-immune 
precipitation experiments were then performed, using 
deletion mutants, to map the region involved in 
dimerization, and to establish whether the previously 
observed inability to bind DNA was linked to an inability to 
form dimers. The results show that the dimerization domain 
of p50 is located between amino acids 201 and 3 67, and that 
this region is responsible for homodimer and heterodimer 
formation. It also suggests that the N terminal region of 
the RHD is involved in interacting with DNA and some 
preliminary data from S. Grimm and P.A. Bauerle indicates 
that less than 3 0 amino acids at the N terminal domain of 
the RHD are sufficient when swapped over to confer p50 DNA 
binding specificity on p65 and vice versa (41), There is 
some published data (43) concerning this same region of the 
RHD in which radiolabelled iodoacetate was used to identify 
which of 5 conserved cysteine residues is involved in p50 
DNA binding (43). This procedure identified a cysteine at 
position 62 which is protected from modification by binding 
to an oligonucleotide containing the binding site. Further 
work in which the five conserved cysteines were mutated in 
turn to a serine confirmed this cysteine 62 to be important 
in the recognition of DNA by p50 (44). The involvement of a 
conserved cysteine in binding of v-rel has also been shown
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by mutation to a serine residue (45).
It has already been mentioned that the C terminal end RHD 
contains a sequence which is composed of positively charged 
amino acids. Using cells transfected with cDNA containing 
mutations in this region, it has been shown that the 
construct became exclusively cytoplasmic with the wild type 
being exclusively nuclear (46). Another study also looked at 
the effect of mutating this Arg-Lys-Arg-Gln-Lys sequence in 
p50 and found that mutations in this short chain of amino 
acids block nuclear translocation in transfected cells (47). 
The corresponding sequence in p65 -Lys-Arg-Lys-Arg- was 
mutated by another group such that the first three residues 
were replaced by uncharged threonine residues. While over 
expression of wild type p65 gave a predominantly nuclear 
localisation, over expression of the mutant did not result 
in any shift of protein from cytoplasm to nucleus (48). 
These results confirm the prediction that these short 
sequences of positively charged amino acids act as a nuclear 
localisation signal (NLS) in both p50 and p65, as has 
already been demonstrated with v-rel in other proteins 
(49).
Although the exact cleavage site of the precursor molecule, 
pl05, is not known (location of the C terminus of p50 is an 
estimate) it has been noted that p65 has an extra 200 amino 
acids in its C terminal region (37,50), Since it is 
established that transcription factors require 
trans-activation domains as well as DNA binding ability, the
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c termini of both p50 and p65 have been tested for 
trans-activation properties. Using a chloramphenicol 
acetyltransferase (CAT) reporter construct under the control 
of two kB sites it has been shown that expression of p65 
leads to a potent transactivation whereas p50 has no effect. 
When p50 and p65 were coexpressed the p50 appeared to reduce 
the transactivation by p65 (35,42). p65 sequences were then 
fused to the DNA binding dommain of GAL4 (a yeast 
transcription factor) to identify the exact region(s) 
involved in the transactivation (35,51). Two transactivation 
domains were identified - TA^ and TA^ - with the principal 
domain TA^ located in the 30 amino acid sequence at the C 
terminal and TA^ in the 90 amino acids located adjacent to 
this. Sequence analysis of TA^ by two different methods 
predicts an amphipathic qc helical structure, with five 
hydrophobic amino acids on one face and five hydrophilic 
serine residues on the opposing face with this structure 
conserved between mouse, human and Xenopus p65. The TA^ 
domain contains a sequence which could be a leucine zipper - 
but neither domain contains a functionally important proline 
rich region which is common in other transcription factors 
(52) .
The information gained on the properties of various 
structural domains suggests that the p50 subunit of NF-kB 
provides the DNA binding activity of the factor and 
dimerises with p65 which then functions as a transcriptional 
activator.
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Function of P50 and d 65
Identification of the transcription factor NF-kB originally 
came about through its DNA binding properties. Purification 
of the factor resulted in two proteins being isolated - p50 
and p65. Reconstitution experiments carried out using the 
two purified proteins (purified from Hela cells) showed that 
a complex was formed when p65 was added to p50 (24). Further 
renaturation experiments showed that p50 could form 
homodimers in solution and the 250kD size of NF-kB DNA 
complex determined by gel filtration could be explained by 
complex formation involving both p50 and p65 subunits. 
Initial experiments looking at DNA binding by ultraviolet 
(UV) crosslinking and renaturation experiments show that 
only p50 is able to bind DNA (23,24). In these studies the 
DNA sequence used was GGGACTTTCC, and the subunits were 
purified from SDS gels. Then came some observations that 
suggested a possible involvement of p65 in DNA binding. 
Firstly it was found that when purified p50 and p65 
co-renatured, the resulting heterodimer had a two fold 
higher binding affinity for the kB binding site than a p50 
homodimer (53). It was then suggested that since in vivo 
most NF-kB binding sites are of low symmetry and also tend 
to consist of pentameric half sites (25) rather than being a 
homodimer binding site, both p50 and p65 are involved. 
Artificial motifs consisting of duplicated pentameric half 
sites were created (Figure 2) and the DNA binding of these 
plus the decameric site was compared between the p50
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homodimer and the heterodimer.
Figure 2
consensus kB site GGGACTTTCC
site AA GGGAC-GTCCC
site BB GGAAA-TTTCC
The p50 homodimer could recognise all three sites but with 
different affinities - recognising the AA site best, 
followed by AB and finally BB. The heterodimer however only 
recognised AB, but with an affinity constant more than two 
times higher than that for the homodimer binding the site.
It was also found that the A half-site is more highly 
conserved than B (25,53) with a consensus of 5'GGGpuN-3' 
compared to 5 *G(GPu)N-3'. Therefore it would appear that the 
p50 homodimer binds with higher affinity to the more 
conserved of the symmetrical sequences.
Studies comparing the effects of different mutations in the 
11 base pair sequence, GGGGATTCCCC, on p50 dimer and p50-p65 
heterodimer binding showed that mutations in positions 1 or 
11 of this motif reduced binding of the p50 homodimer much 
more than that of the heterodimer. If the motif was mutated 
to GGGGACTTTCC, homodimer recognition was reduced 70 fold
but heterodimer binding only fell 3 fold. This data suggests 
that the presence of p65 lowers the requirement of p50 for 
the complete 11 base pair motif and for symmetrical motifs 
(113). Binding competition experiments show that, in
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contrast to p50, p65 binds preferentially to the BB motif 
described previously. This suggested that when NF-kB binds 
to DNA the p50 contacts the highly conserved A half site 
while p65 contacts the less conserved B site. UV 
crosslinking experiments were then carried out and the 
results show a direct participation of p65 in the DNA 
binding of NF-kB. Also shown is a preferential binding of 
p50 to the A half site and p65 to the B half site.
Further evidence of p65 binding to DNA was obtained in 
experiments using p65 from Baculovirus infected insect cells 
(55) and in vitro translated p65 (50). Homodimers of p65 
have been shown to bind a different consensus sequence to 
that preferred by p50 homodimers - namely GGGPuNTTTCC (56). 
The '10th and 11th base pairs are not essential, and the 
TTTCC region is highly conserved.
The differential binding requirements of the 2 subunits 
composing the dimeric transcription factor, NF-kB, allows 
evolution of regulatory elements which are recognised by 
p50-p65 heterodimers but not homodimers. The role of 
homodimer specific binding sites in gene regulation is as 
yet unclear. (41)
The I-kB Inhibitor System.
Purification and Specificity
As well as the structural similarities between the rel 
family of proteins, and their common property of cytosolic 
to nuclear translocation, they also have inhibitor proteins 
associated with them. For NF-kB, this inhibitor protein is
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I-kB, which is now recognised as belonging to a different 
family of proteins, the ankyrin family.
As already discussed, in non stimulated cells, NF-kB DNA 
binding activity is not detectable in nuclear or cytosolic 
fractions. However if the cytosolic fraction is treated with 
deoxycholate followed by NP-40, then a kB specific DNA- 
binding activity is seen, which has been shown to be 
identical to that seen in the nuclei of activated cells 
(24,25,26,32). This deoxycholate treatment results in
release of a protein which was termed I-kB (57). Its
inhibition of the NF-kB complex is reversible, saturable, 
and specific ; I-kB does not interfere with DNA binding of 
any,other factor tested so far. In subcellular fractionation 
experiments, the NF-kB/I-kB complex shows a cytosolic 
localisation, but this could be an artefact of the 
fractionation procedure and so enucleated cells were
examined for the NF-kB/I-kB complex.These experiments showed 
that a large proportion of the complex was indeed 
cytoplasmic.
The cytosol of human placenta was used as the source for the 
first purification of I-kB to homogeneity (58). I-kB
released from its complex with NF-kB by deoxycholate 
treatment was then purified further by chromatography to 
yield two peaks of activity. The majority of I-kB activity 
(~80%) is referred to as I-kBoc and the remaining 20% as 
I-kBp. Renaturation experiments show I-kB(X to be a protein 
of 37kD while I-kBp is of higher molecular weight. Multiple
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chromatography steps were used in a separate purification 
process (59), resulting in a 35kD I-kB protein purified from 
rabbit lung. This presumably corresponds to the I-kBx from 
human placenta. In a glycerol gradient, purified I-kHx 
sediments with a size of 35 - 40kD, and in gel filtration
elutes at 70kD which suggests it may form labile dimers.
A modified purification procedure was developed and used to 
further purify I-kBp (60). Previously its molecular weight 
had been narrowed down to between 40-43kD (58) but the 
purification step used to further isolate I-kBx could not be 
used due to the proximity of the I-kBp peak to that of non 
specific contaminants. Once finally purified, the I-kBp was 
found to have molecular size of 43kD. Both I-kBx and I-kBp 
have similar isoelectric points ; between 4.8 and 5.0.
The 35kD.I-kBp purified from rabbit lung (59) was shown to 
be inactivated by treatment with protein kinase C and cAMP 
dependent protein kinase. When the same treatment was used 
on both I-kB(X and I-kBp from the human placenta, their 
inhibition of DNA binding by NF-kB was abolished in the 
presence of ATP. Treatment with immobilised alkaline 
phosphatase also abolished inhibition by I-kBp, but had no 
effect on I-kBoc suggesting that I-kBp has been purified as a 
phosphoprotein, and that phosphoryl group(s) are necessary 
for its inhibitory activity. Phosphatase treatment also 
activates DNA binding of NF-kB in complex with I-kBp 
Both I-kB species preferentially bind p65 rather than p50, 
as indicated by a number of observations. The homodimer of
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p50 cannot be inactivated by I-kB, whereas heterodimeric 
NF-kB can (58) which suggests I-kB interacts with p65. 
However the presence of p65 in the heterodimer could 
influence p50 in some way that enabled it to bind I-kB, or 
p65 could bind I-kB directly. Preincubation of I-kBx with 
p65 abolishes inhibition of DNA binding by the heterodimer, 
but preincubation of I-kBoc with p50 has no effect. The 
complex formed between p65 and I-kBoc does not react with p50 
homodimers or inhibit DNA binding of the homodimers (53). 
The same study also showed that a complex of p50-p65-IkB 
could be activated in a dose-dependent manner by the 
addition of increasing amounts of p65. The resultant 
activation was more effective than that seen with 
deoxycholate.
Further evidence for p65 being a receptor for I-kB came from 
two studies which show that I-kB can inhibit DNA binding of 
NF-kB and p65 homodimers but not p50 homodimers (54,57). 
This was shown by titration and kinetic analysis in which 
increasing amounts of I-kB were added to excess NF-kB 
resulting in dose-dependent inhibition of DNA binding. 
Addition of I-kB to p50 homodimers had no effect.
As mentioned previously, p65 has a unique C terminal region, 
and these results may suggest that the site for I-kB binding 
is located in this region, rather than in the RHD. However, 
it has been shown that DNA binding of truncated p65 can be 
inhibited by I-kB and so the I-kB binding site on p65 must 
map to the RHD (37). This was confirmed by mapping of the
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binding site to the C terminal domain of the RHD (61). 
Cloning of I-kB Proteins
The first I-kB cloned was identified unintentionally - in 
that the C terminal domain of pl05 is now recognised as 
I-kB%.
The C terminal region of this precursor protein has been 
shown to contain eight ankyrin repeats and to exert a 
trans-inhibitory effect on NF-kB DNA binding (62,63), In 
contrast to the other I-kB proteins, this I-kB% shows a high 
affinity for p50, and can displace p50 DNA binding in less 
than 5 minutes. As with the other proteins, the ankyrin 
repeats are necessary for the inhibitory activity of I-kBx. 
As , well as being identified as the C terminal region of 
pl05, I-kBx has also been expressed from a separate 2.6kb 
mRNA which is expressed in murine lymphoid cells (63). The 
70kD I-kBx is identical to the protein encoded by the C 
terminus of pl05. As found in pl05, the p70 protein contains 
a glycine rich domain and a series of ankyrin repeats. 
Comparison of the homologous ankyrin region in different 
I-kB's shows that the sequences of these repeats align best 
when comparison is made between the first repeat of each 
gene, second is compared with second, and so on.
Studies on the adherence of monocytes to plastic led to the 
discovery of a gene, MAD-3, expressed early after adherence 
(64). The transcripts obtained are 1.6kb in size, with a 
predicted polypeptide sequence of 317 amino acids which 
should encode a 34kD protein. Structural predictions suggest
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an arrangement in three domains. A stretch of 72 hydrophilic 
amino acids with consensus sequence DEEYEQMVK is found in 
the N terminal domain while the C terminal has a consensus 
sequence for PKC phosphorylation (RPSTR) and a region rich 
in PEST sequences which are associated with rapid protein 
turnover. The internal domain is made up of 5 repeats of the 
ankyrin motif (65).
The MAD-3 translation product was shown to specifically 
inhibit NF-kB DNA binding activity but to have no effect on 
the DNA binding of p50 homodimers. Partial amino acid 
sequence showed MAD-3 to be highly related if not identical 
to the 35kD I-kB purified from rabbit lung (59).
Due to the presence of ankyrin repeats, the proto-oncogene 
Bcl-3 (associated with chronic lymphocytic leukaemia)(66), 
was tested for I-kB activity. In band shift and gel 
retardation assays (62,67) Bcl-3 has been shown to inhibit 
DNA binding by p50, and to a lesser extent, by p65. This 
inhibition is due to the ankyrin repeat domain of Bcl-3. 
Phosphopeptide mapping experiments (68) using Bcl-3, IkBp, 
and I-kBx show that I-kBX and Bcl-3 share phosphopeptides 
while I-kBp and MAD-3 are not related. N terminal truncation 
of Bcl-3 alters its inhibition such that this shortened form 
is a potent inhibitor of p65 but not p50, which is the same 
specificity as that of I-kBx (69). This truncation may also 
occur in vivo, since immunoprécipitation with anti Bcl3 
antibodies yields a 37kD protein, rather than its expected 
50kD size. It has also been shown that rabbit polyclonal
-  22 -
antiserum raised against MAD-3 can reduce inhibition of 
NF-kB DNA binding by I-kBoc, but not I-kBp (43).
Functions of I-kB.
since I-kB was originally identified due to its inhibition 
of DNA binding of NF-kB, at least one of its functions was 
known at the start. The cytoplasmic NF-kB/I-kB complex 
showed a size of around 150kD in both gel filtration and 
glycerol gradients (57,58) and this suggests a heterotrimer 
of p50, p65, and I-kB. Inactivation or removal of I-kB from 
the complex would then release p50-p65 heterodimer which 
form active complexes able to enter the nucleus.
The mechanism of inhibition by I-kB is not Well understood. 
MAD-3 and I-kBx bind complexes that contain p65 and inhibit 
DNA binding of these complexes, but cannot associate with 
p50 homodimers (24,53). This binding to p65 has been mapped 
to the RHD of p65 (37). I-kBp can also inactivate NF-kB
containing the p65 subunit but will also inactivate 
complexes containing C-rel (58). In contrast, I-kBx inhibits 
DNA binding of p50 homodimers as well as that of p50-p65 and 
p50-C-rel (63).
In NF-kB/I-kB complexes containing I-kBx or I-kBp, 
phosphorylation of the I-kB is required to activate the 
NF-kB DNA binding (59). For I-kBp,phosphorylation by either 
PKA or PKC will remove inhibition, but with I-kBx only PKC 
phosphorylation will suffice (69). Phosphatase treatment of 
I-kBp inactivates its inhibitory activity, whereas it has no 
effect on I-kBx. The size and phosphorylation
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characteristics of I-kBp suggest homology with the rel 
associated pp40 protein isolated by immunoprécipitation from 
avian cell extracts (69).
Investigation of the kinetics of inhibition of I-kBx and 
I-kBp on preformed NF-kB DNA complexes show that addition of 
I-kBx reduces the half life of the complex to 3 minutes and
I-kBp reduces it to 7 minutes (58). The dissociation 
reaction displayed higher order reaction kinetics, therefore 
both inhibitors dissociate NF-kB already bound to DNA and, 
if found in the nucleus, could function as inhibitors of 
NF-kB mediated transcription.
Another function of I-kB is to control nuclear uptake of 
NF-kB. The complex of NF-kB and I-kB was first identified in 
the cytosol of cells, and could not be removed by 
enucleation - therefore showing it to be a truly cytoplasmic 
complex (57). Studies on transfection systems show that 
co-transfection of p50 and p65 encoding plasmids with a 
MAD-3 expression plasmid results in accumulation of p50 and 
p65 in the cytoplasm rather than the nuclear distribution 
seen in the absence of MAD-3 (61). Another similar study 
looked at the effect of MAD-3 on the distribution of 
over-expressed p50 and found that addition of MAD-3 resulted 
in only a partial redistribution of p50 to the cytoplasm 
(48). In the same study, over-expressed MAD-3 was observed 
in both the nucleus and cytoplasm when microinjected into 
Vero cells. This was shown to occur even at a very low level 
of expression. However no NLS sequence has been found in
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MAD-3 as yet, so it is possible that this distribution is 
due to passive nuclear uptake of the 35kD protein. 
Co-expression of plasmids containing MAD-3 and p65 show that 
each could inhibit nuclear uptake of the other, although p65 
was less efficient at preventing uptake of MAD-3.
The control of nuclear uptake of p50 and p65 by MAD-3 
suggested that MAD-3 may interact with or block the NLS of 
these proteins. Antisera were raised against peptides 
overlapping these NLS’s (47,48) and used to investigate 
whether they could block I-kB binding or vice versa. 
Immunoprécipitations show that only nanogram amounts of 
MAD-3 are sufficient to block immunoprécipitation of p65 by 
antibodies against the p65 NLS. However MAD-3 had no effect 
on precipitation of p50 by anti-p50 NLS antibodies. In the 
presence of p65, immunoprécipitation of p50 by anti-p50 NLS 
antibodies was inhibited by MAD-3, suggesting that in the 
p50-p65 complex, binding of MAD-3 to p65 masks the NLS of 
both proteins.
A further two observations support NLS masking by I-kB (61). 
Fusion of the NLS of SV40 to p65 expression vectors gave 
nuclear expression of p65 which remained unaffected on the 
addition of MAD-3. Deletion or mutation of four NLS amino 
acids in p65 resulted in a protein which could no longer 
bind MAD-3, as determined by gel shift and 
COimmunoprécipitation. It seems very probable therefore that 
MAD-3 binds directly to the p65 NLS.
The precursor molecule pl05 which contains both a DNA
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binding domain (p50) and an inhibitor domain (I-kB%) shows 
an exclusively cytoplasmic distribution when over-expressed 
in Vero cells and Cos cells (47). It has been shown that 
pl05 cannot bind to DNA (70). Further studies showed that 
addition of pl05 to a DNA binding assay inhibits DNA binding 
by p50 (71) and p65, with the inhibition of p65 requiring a 
similar concentration of pl05 or MAD-3. The 70kD I-kB% 
isolated from murine cells also inhibits DNA binding of p50 
heterodimers (63). When p50 and pl05 are mixed a complex of 
about 170kD is obtained, suggesting a direct interaction 
between pl05 and p50 to form a heterodimeric complex. 
Cotransfection of pl05 and p50 or p65 results in a shift 
from nuclear to cytoplasmic localisation of p50 or p65 (71). 
Again using antisera raised against a peptide encompassing 
the NLS of pl05, it has been shown that in pl05 the NLS 
sequence is masked (47). Truncations at the C terminal end 
of pl05 enabled recognition of the NLS, as did dénaturation 
of pl05.
Therefore, it seems likely that in pl05 the c terminal I-kBx 
folds over to mask the NLS of p50 and thus retain the 
molecule in the cytoplasm. This association can also be 
maintained after cleavage of the molecule, thereby retaining 
p50 in the cytoplasm.
Activation of NF-kB and Its Control
The transcription factor NF-kB is composed of and controlled 
by several subunits belonging to two protein families : the 
rel and ankyrin families. Activation of the factor is
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mediated by a wide range of stimuli in many different cell 
types and results in induction of many inducible genes.
The activation of NF-kB in vitro can be effected by various 
reagents which release I-kB from the cytoplasmic complex. 
These include sodium deoxycholate, protein phosphatases, low 
pH and protein kinases - which have all been mentioned 
already. Protein kinases appear to have a significant role 
to play, both in their own right and in their role as second 
messengers. Both PKA and PKC have been shown to activate DNA 
binding activity of NF-kB in the cytosol of pre B cells 
(72). Agents which activate protein kinase C have also, not 
surprisingly, been shown to induce DNA binding of NF-kB. 
These include active phorbol esters such as TPA, PMA, (9), 
PDB (73) and bacterial LPS (9). A recent report shows that 
activation of NF-kB in Xenopus oocytes through ras p21 or 
phospholipase C (PLC)-mediated phosphatidylcholine (PC) 
hydrolysis involves PKC^ (74). NF-kB activation only occurs 
when the Xenopus oocytes are stimulated into their 
maturation programme by insulin and not progesterone, 
showing that NF-kB only transmits signals to specific 
pathways.
Lectins, including PHA and Con A, can also activate NF-kB in 
T cells when used in conjunction with a phorbol ester. This 
pathway is also thought to be PKC mediated and results in 
expression of genes under the control of kB elements. In T 
cells, these include the HIV enhancer (74), the cytokine
11-2 (75), and the alpha chain of its high affinity receptor
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( 76 ) .
The ability of cytokines to activate NF-kB has elicited much 
research. Both interleukin-1 (Il-l) and tumour necrosis 
factor oc (TNFk ) have been shown to activate NF-kB 
(77,78,79). The mechanism by which these agents activate 
NF-kB is still not completely clear, although reactive 
oxygen intermediates (ROI) have been shown to play a role in 
so far as counteracting the effect of ROI's using 
N-acetyl-L-cysteine (NAC) prevents activation of NF-kB by 
HgOg. It has also been shown that PKA and PKC can both 
trigger NF-kB activation and nuclear translocation in vitro 
(72), so this seems a likely activation pathway. Il-l 
binding to cells has also been shown to lead to production 
of diacylglycerol (80), which is an activator of PKC thus 
suggesting Il-l activation of NF-kB may be mediated through 
either protein kinase.
Both TNRx and TNFp can activate NF-kB, via a pathway that 
does not require an increase in cellular cAMP levels (81). 
Neither cytokine has any effect on cAMP levels in HL60 
cells. NF-kB activation occurs while the level of cAMP stays 
the same and the use of agents which increase levels of cAMP 
does not lead to NF-kB activation in these cells. The 
mechanism of NF-kB activation by TNRx does not involve 
activation of PKC as shown by studies on the cell lines 
Jurkat and K562 (another human leukaemic cell line) (82). 
The use of the protein kinase inhibitors H7 and 
staurosporine completely blocked activation of NF-kB by PMA
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but had no effect on TNHx mediated activation. In Jurkat 
cells depleted of PKC, TNEx could still induce NF-kB 
activity. TNRx activation of NF-kB occurs very quickly, with 
high levels of NF-kB activity seen after only 2 - 4  minutes 
of addition to cells (83). This activity could be maintained 
for more than 3 hours but required continual protein 
synthesis and continual TNBx stimulation. In the same cell 
line (HL60), induction by PMA took 30 - 45 minutes and was 
totally dependent on protein synthesis, while in 70Z/3 cells 
induction was more rapid, and independent of protein 
synthesis. Both TNFk  and PMA also induce NF-kB mRNA in Hela 
cells (36). Other cytokines such as 11-2, 11-4 and IFN% do 
not activate NF-kB.
Other factors which can lead to induction of NF-kB activity 
are varied in type and include protein synthesis inhibitors 
(mentioned previously), double stranded RNA (84,85), damage 
to DNA ( by UV light treatment with maximum induction after 
2 hours) (86), viral transactivators and the parasite 
Theileria oarva (reviewed in 87).
It appears that multiple pathways and signalling systems are 
involved in the induction of NF-kB in different cell types. 
Many do not require de novo protein synthesis thereby 
activation involves post-translational modification.
This post-translational modification is thought to involve 
phosphorylation of I-kB. It has been shown in vitro that 
purified I-kB's can be phosphorylated by PKC and PKA (63), 
but treatment of I-kB<x with PKC abolishes inhibition while
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treatment with PKA has no effect (59), The PKC preparation 
used was an impure preparation consisting of a mixture of 
different isotypes. Both forms of I-kB purified from human 
placenta can be inhibited by both PKA and PKC (60) but 
phosphorylation of pp40 (homologue of I-kBx from chicken 
cells) by PKA results in inactivation whereas PKC has no 
effect (69). It has now been shown that LPS activation of 
THP-1 cells and cytokine stimulation of Hela, Jurkat, or 
70Z/3 cells all result in phosphorylation of I-kBx, 
providing evidence that this does take place in vivo. 
Following dissociation of I-kBey from the complex, mediated 
by phosphorylation, the inhibitor is degraded by proteases 
similar to chymotrypsin, namely TLCK (Na-p-Tosyl-L-Lysine 
Chloromethyl Ketone) and TPCK (Na-p-Tosyl-Phenylalanine 
Chloromethyl Ketone) (88). Inhibitors of these proteases 
block activation of NF-kB - as shown in PMA activated 70Z/3 
cells or TNBX activated Jurkat cells. This argues that 
phosphorylation of I-kBx is not sufficient for activation, 
but that degradation is also required.
Following cell activation, phosphorylation and degradation 
of I-kBx, the inhibitor protein reappears in the cytoplasm 
about 2 hours later (89,90). Induction of NF-kB DNA binding 
activity, degradation of I-kBx and induction of I-kBx mRNA 
gene expression were all blocked by use of 
pyrrolidinedithiocarbamate (PDTC) which is a metal chelator 
and free radical scavenger. This inhibition has been shown 
in many studies (90,91,92,93) using various antioxidants,
-  30 -
thus suggesting a role for reactive oxygen intermediates in 
the activation of NF-kB.
In transfected cos-7 cells, p65 expression is required to 
induce I-kB(x mRNA expression and protein production. This is 
also the case in transfected Jurkat cells. Association of 
I-kB(x with p65 increases the half life of I-kBx from 40 
minutes to 4 hours (89). This has been shown in other 
transfection systems (94,95) indicating the existence of an 
autoregulatory loop which maintains NF-kB complexed with 
I-kB in the cytoplasm until a specific activation signal 
induces translocation to the nucleus.
NF-kB Activation of HIV
Human Immunodeficiency Virus (HIV) is a retrovirus which 
infects cells expressing surface CD4, including T 
lymphocytes and cells of the macrophage lineage. This virus 
is the causative agent of acquired immunodeficiency syndrome 
(AIDS) (96), and so is the subject of much research, not 
least to investigate events involved in cell-virus 
interactions at the molecular level.
T cell activation can lead to production of HIV virus from 
latently infected cells. The long terminal repeat (LTR) of 
the HIV virus contains two NF-kB binding sites, and mutation 
of these sites abolished induction of virus production 
(23,97). Jurkat cells transfected with the viral tat 111 
gene (encoding a potent activator of viral gene expression) 
(98) were used to investigate the effect of NF-kB on viral 
transcription and showed that the two factors act
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synergistically to increase viral gene expression. In cells 
of monocyte/macrophage lineage, promonocytes do not 
constitutively express NF-kB until activated by agents such 
as TPA (73) or LPS (99). TPA stimulation of promonocytes 
results in transactivation of the HIV enhancer while in 
differentiated cells there is a high basal level of activity 
that is not affected by TPA stimulation.
HIV transcription in T cells is barely, detectable in vivo. 
(100) with very little basal activity of the HIV enhancer 
and low nuclear NF-kB expression (101). In tissue 
macrophages continual virus transcription results in 
detectable levels of HIV proteins (102) and it has been 
shown that chronic HIV infection leads to induction of NF-kB 
and a permanent increase in HIV enhancer activity (103). 
This chronic infection also induces nuclear translocation of 
NF-kB - suggesting that in monocytes, HIV infection can also 
induce its own LTR transactivation. This HIV induced 
translocation does not involve a PKC pathway, as shown by 
PKC inhibitors (104). Analysis of the nuclear complex shows 
that it is a heterodimer of p50 and p65. Activity of the 
pl05 promoter is also increased in chronically infected 
cells in a kB dependent manner. This shows that HIV exploits 
the characteristic of autoregulation of NF-kB functions. 
Since PKC is not involved in the HIV mediated NF-kB 
activation, other mechanisms such as those discussed 
earlier for TNF or Il-l stimulation may be involved, althogh 
neither cytokine is produced by HIV infection (103).
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In T cells, it has been shown that HIV proviral DNA can 
produce infectious virus within 9 days in the absence of 
both kB sites from the enhancer, while the wild type 
provirus virus is produced within 5 days (105). In these 
cells, deletion of Sp-1 sites abolishes viral production ~ 
suggesting that, in the absence of NF-kB, Sp-1 can activate 
the HIV enhancer with lower efficiency than NF-kB. The 
importance of NF^kB in HIV activation varies from cell to 
cell and is markedly cell type specific.
Aims of study
The aims of this study were to produce polyclonal ond 
monoclonal antibodies against different subunits of the 
NF-kB family and against the cloned I-kB, MAD-3, and to use 
these antibodies to determine the subcellular localisation 
of these proteins in different cell types before and after 
activation by various stimuli.
Ultimately it is hoped that the work reported herein may 
contribute to the understanding of the events involved in 
the induction of latent HIV-1 to infectious virus in cells 
of the immune system, especially the role of NF-kB in this 
activation and the potential inhibition of this by the 
family of I-kB proteins.
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MATERIALS AND METHODS
1. Cells and Tissue Culture Media
Jurkat cells (T cell leukaemia cell line) were grown as a 
suspension in RPMI medium (GIBCO) containing 10% foetal calf 
serum (Sera Lab Ltd). A549 cells (human lung carcinoma cell 
line) and Hela cells (human cervical carcinoma cell line) 
were grown as monolayers in Glasgow modified Eagle's Medium 
containing 50 units/ml of penicillin and 50 ^g/ml of 
streptomycin (G-Mem GIBCO) supplemented with 5% newborn calf 
serum (Sera Lab Ltd) while MG63 cells (human osteosarcoma 
cell line) were also grown as monolayers in the same medium 
as above but supplemented with 10% PCS. All cell lines were 
maintained at 37°C.
2. Production of Polyclonal Antisera,
a. Against Peptides
Peptides corresponding to the following regions of proteins 
were synthesised by Paul Talbot (Department of Cell and 
Molecular Biology, University of St. Andrews) ; N and C 
termini of NF-kB pl05, N and C termini of MAD-3, C terminal 
of p65 rel, and a region of ankyrin. Each peptide was 
synthesised using solid phase fluorenylmethoxycarbonyl 
polyamide chemistry on a CRB Pepsynthesiser 11 with a 
terminal cysteine residue to enable coupling to the linker 
molecule - this cysteine was at the C terminus of N terminal 
peptides and the N terminus of C terminal peptides. The 
peptide purity was determined by FPLC, The linker molecule 
SPDP (SIGMA,106) was coupled to a carrier protein Human
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serum albumin (HSA, SIGMA), the carrier plus linker was then 
coupled to the peptide and efficiency of coupling checked by 
spectrophotometry. The coupling reaction is shown below in 
Figure 3.
Figure 3.
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This method of coupling was chosen for many reasons. Its 
advantages include its speed and efficiency at pH 5 to 9, 
and most importantly, the fact that the amount of coupling 
can be quantified by spectrophotometry. The reaction is done 
in two stages, with the coupling of the carrier protein to 
SPDP being done first, and the efficiency checked by 
measuring the amount of pyridine-2-thione released on 
addition of dithiothreitol (DTT). Assuming a reasonable 
amount of coupling has been achieved (greater than 50%)
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coupling of the peptide is then done. Again the efficiency
of the coupling is checked before the preparation is
aliquoted and stored at -20°C. An example of the
calculations done to check the level of coupling at both
stages is shown below.
Efficiency of coupling is calculated using the formula:
A = Ec
where A = absorbance at 343nm
E = molar extinction coefficient for 
pyridine-2-thione 
c = concentration
1. Coupling of HSA to SPDP
A = 6.6 E = 8.08 X 10^
c = 6.6/8.08 X 10^
= 8.2 X 10"4 => 0.82mM
concentration of lysine in HSA = molarity of HSA x no.
of lysine residues 
= 20 X 0.06 
= 1.2mM
efficiency of derivatisation = 0.82/1.2 x 100%
= 68%
2. coupling of peptide of HSA-SPDP 
A — 3.6
C = 3.6/8.08 X 10^
= 0.44mM
efficiency of coupling - 0.44/0.68 x 100%
= 65%
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200jiig of coupled product in 1ml PBS was mixed with 1ml 
Freunds complete adjuvant (SIGMA) and sonicated until a 
viscous white emulsion was formed. Two Dutch female rabbits 
(Hyline) were each subcutaneously injected at 4 sites with 
1ml of this emulsion. The rabbits were boosted every two 
weeks with the emulsion containing Freund's incomplete 
adjuvant (SIGMA). 5ml of blood was removed by ear bleed 
from each rabbit prior to immunisation (preimmune bleed) and 
one week after each subsequent immunisation (test bleed).
b. Against Proteins
Rabbit polyclonal antisera were raised against cloned, 
bacterially expressed purified NF-kB p50, MAD-3, ankyrin 
repeat protein and p65-GST fusion protein (all obtained from 
E. Jaffray or J. Nicholson, both Department of Cell and 
Molecular Biology, University of St. Andrews.). The region 
of each protein expressed is shown below:
protein amino acids expressed
p50 35 - 381
p65 12 - 317
I-kB 1 - 317
ankyrin 509 - 307
lOOjug of purified protein or fusion protein in 1ml PBS was 
mixed with 1ml Freund's complete adjuvant (SIGMA) and 
sonicated to form an emulsion as above. Two Dutch dwarf 
female rabbits (Hyline) were each subcutaneously injected 
with 1ml of emulsion at four sites. The rabbits were then 
given a booster injection two weeks later with emulsion
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prepared as before but this time with Freund's incomplete 
adjuvant. Subsequent boosts, all prepared with Freund's 
incomplete adjuvant, were given at four weekly intervals. 
Preimmune and test bleeds were collected as above. A guinea 
pig was also boosted using the same protocol as for the 
rabbits, but only two test bleeds were taken, by heart 
puncture, after 3 boosts and 5 boosts. In accordance with 
Home Office regulations the guinea pig was then sacrificed. 
The blood was allowed to clot at room temperature for one to 
two hours then the clot loosened and the sera separated by 
centrifugation at 1200 rpm for 10 minutes. The sera was then 
stored in 0.5ml aliquots at -70°C. Once removed from -70° 
sodium azide was added to 0.1%, and the serum further 
aliquoted and stored in 50jul volumes at -20°C.
Once the titre of the test sera had plateaued, as determined 
by ELISA, the rabbits were sacrificed and bled out. The sera 
was separated as above but stored at -70°C in 1ml aliquots.
3. Enzyme Linked Immunosorbent Assay (ELISA)
a. To Determine Titre of Peptide Antisera.
Immulon 2 96 well plates (DYNATECH) were coated with 1% 
gluteraldehyde in PBS overnight at 4°C. Plates were then 
washed once with PBS and the peptide plated out at lOpg/ml 
in PBS. The carrier protein and an unrelated peptide were 
also included as controls. After incubation at room 
temperature for 1-2 hours, the peptides were removed and the 
plates dried at 37°C for 15 minutes. Wells were then blocked 
by incubating with 10%(w/v) non-fat powdered milk (Marvel)
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and 0.1%(v/v) Tween 20 (SIGMA) at 37°C. The wells were 
washed three times with 1%(w/v) Marvel, 0.1%(v/v) Tween 20 
in PBS before addition of the sera to be tested. Sera were 
assayed in duplicate in doubling dilutions from to
V i o 240' leaving the 1st column of each plate blank. The 
primary Ab was left for 1 hour at room temperature, the 
wells then washed three times as before and the second 
antibody, donkey anti-rabbit horseradish peroxidase (SIGMA), 
was added to all wells at a V ^ q o o o dilution. This was
incubated for 1 hour again at room temperature, the plates
washed three times as before and the substrate TMB
(DYNATECH) added. Plates were left in the dark for 20 
minutes then read on an MR2000 plate reader (DYNATECH) at
630nm. Some of the ELISA's were performed using OPD
(o-phenylene-diamine,SIGMA) as a substrate - these plates 
were read at 493nm.
b. Protein.
96 well plates (Immulon 2, DYNATECH) were coated with
protein at a concentration of lOjig/ml in buffer containing
0.035M NaHCOg and 0.015M Na^CO^ (pH 9,6) and incubated at 
room temperature for 1 hour or overnight at 4°C. The protein 
solution was then removed and the wells dried and blocked as 
before. The procedure was continued as above.
4. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Biorad Mini Protean System Gel Rigs were assembled and used 
in accordance with the manufacturers instructions. 10% 
running gels were prepared using a 30% acrylamide stock
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(29.25% acrylamide, 0.75% N,N'-methylene-bis-acrylamide) and 
also contained 0.375M Tris-HCL, pH8.9, 0.1% SDS, and V 250 
volume of 25%(w/v) ammonium persulphate. Immediately before 
pouring the gel, V 2500 of TEMED (KODAK) was added to
catalyse polymerisation. Once poured, the running gels were 
overlaid with isopropanol to prevent air bubbles and 
maintain an even surface - this was then removed and the gel 
surface rinsed with H^O once the gel had polymerised. The 
stacking gel contained 5% acrylamide, 0.105M TrisHCl (pH
6.7), 0.1% SDS and APS as before. Again TEMED was added
immediately prior to pouring the gel. Samples were denatured 
prior to loading on the gel by heating at 100°C for 2 
minutes in 30%(v/v) glycerol, 15%(v/v) p-mercaptoethanol, 
6%(w/v) SDS, 0.128M Tris-HCl pH 6.7 and 0.05% bromophenol 
blue. Electrophoresis buffer contained 0.025M Tris-HCl, 
0.19M glycine and 0.1% SDS, and electrophoresis was done at 
150 Volts.
5. Western Blotting
Separated proteins were transferred from SDS-PAGE gels to 
nitrocellulose membrane (Amersham) using a semidry blotter 
(Ancos) in a 20% methanol (v/v), 0.02M Tris pHS.O transfer 
buffer by applying a current of 80mA for 60 minutes. The 
nitrocellulose membrane was blocked for 1 hour at 20°C in 
PBS, 0.1% Tween-20 (v/v), 5%(w/v) non fat powdered milk
(Marvel), PTM, then incubated with antibody appropriately 
diluted in PTM for 1 hour at 20°C. The membrane was then 
washed twice in PTM before addition of horse radish
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peroxidase conjugated second antibody - either donkey anti­
rabbit immunoglobulin or sheep anti-mouse immunoglobulin 
(both Amersham, diluted 1:3000 in PTM) for 30 minutes at 
2 0°C. The membrane was again twice washed in PTM, then 
finally once in PBS, 0.1% Tween before incubating the 
membrane in enhanced chemiluminescence (ECL) detection 
reagent (Amersham) and visualisation on X-ray film.
In some cases, after the primary antibody, and subsequent 
washes the antigen antibody complex was detected by addition 
of ^^^I-Protein A diluted in 5ml PTM for 60 minutes at 2 0°C 
The nitrocellulose was then washed extensively in PBS until 
the background count dropped to 2-5 cps then exposed to 
X-ray film overnight at -70°C. Prestained molecular markers 
(Biorad) were run but were too faint to photograph, so the 
size of the bands was marked on the autorads.
6. Affinity Purification of Polyclonal Antisera.
Affinity chromatography was carried out using 1ml HiTrap NHS 
activated columns (Pharmacia). The appropriate purified 
protein was coupled to the NHS activated Sepharose as 
described in the manufacturer's instructions.
Firstly, the antibody solution was passed over a resin with 
bound GST and the flow through collected, then the affinity 
column pre-equilibrated with lOmM Tris-HCl (pH7.5). 1ml of 
polyclonal antisera was spun in a microfuge for 2 minutes to 
clear any debris and then diluted 1 in 10 in lOmM Tris-HCL 
(pH7.5). This was loaded onto the column in 1ml volumes - 
each being left on the column for 20 minutes to maximise Ab
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binding. The flow through was collected and then loaded 
again in 1ml fractions, this time being left on the column 
for 10 minutes. The column was then washed with lOml-lOmM 
Tris (pH 7,5), then with 10ml lOmM Tris, 500mM NaCl (pH 
7.5). Bound antibody was eluted using twenty 0.5ml aliquots 
of lOOmM glycine-HCl (pH 2.25) and collected in 50jul IM Tris 
(pH 8.0).
The fractions were tested for specific antibody activity in 
dot blot and Western blot analysis,
7. Immunofluorescence
Cells, either A549, Hela, or MG63, were grown on circular 
glass coverslips in wells on 24 well plates to about 80-90% 
confluence. The cells were then activated for the
stipulated time using TNRx (SIGMA) at lOng/ml (in the case
of MG63 the cells were serum starved overnight prior to 
activation). After the appropriate activation time, cells 
were immediately washed once quickly in ice cold PBS then 
fixed for 10 minutes in 5%(v/v) formaldehyde, 2%(w/v)
sucrose in PBS, followed by 2 washes in 1% normal donkey 
serum (SeraLab) in PBS. If not to be used immediately, the 
coverslips were stored at 4°C in PBS, 1% normal donkey
serum, 0.1% NaN^, and rinsed once in PBS before use. The 
cells were permeabilised for 5 minutes at 20°C in PBS, 1% 
normal donkey serum, 10%(w/v) sucrose, and 0.5% NP40 then 
washed twice in PBS, 1% normal donkey serum and once in 
PBS.
The primary antibodies were diluted as required in PBS, 1%
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normal donkey serum and pipetted onto a glass slide in a 6pl 
drop. Coverslips were carefully inverted onto the antibody 
drop, the slides transferred to a moist chamber and 
incubated overnight at 4°C. The coverslips were then washed 
for 1 minute in permeabilisation buffer, 3 minutes in 3 
changes of wash buffer and 1 minute in dH^O.
Bound proteins were then visualised using FITC-conjugated 
donkey antirabbit IgG (if rabbit primary antisera were used) 
or Texas Red conjugated donkey anti-mouse IgG (both from 
Jackson ImmunoResearch Laboratories Inc.) diluted /^^ qq 
wash buffer. The antibodies were applied as before and 
incubated for 60 minutes at 2 0°C, then cells were washed as 
before.
The cells were mounted in a glycerol/PBS solution (Citifluor 
Ltd) - the mount was pipetted onto a glass slide in a l;5pl 
drop and the coverslip inverted onto it, taking care to 
avoid air bubbles. The upper (non cell) side of the
coverslip was dried carefully and the coverslip sealed with 
nail varnish before viewing under a Nikon Microphot 
conventional immunofluorescence microscope or a laser 
scanning confocal microscope (Bio-Rad 500).
8. Production of Monoclonal Antibody
a. Immunisation
Img of purified p50 was diluted to SOOjil in PBS then 
denatured by heating to 70°C for 15 minutes. This was then 
mixed with Img of native purified p50 in lOOpl PBS, and 1ml 
of Freund's complete adjuvant (SIGMA). The mixture was
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sonicated until a viscous white emulsion was formed, then 
200jUl of this emulsion was injected into each of 10 Balb/c 
mice intraperitoneally. The mice were each boosted again two 
weeks later but this time the emulsion contained Freund's 
incomplete adjuvant (SIGMA), 7 days later, a test bleed of
SOJxl was taken from each mouse by tail vein bleed, and the 
sera tested by dot blot and Western blot analysis against 
both native and heat denatured p50.
The 4 mice giving the best response were boosted once more 
each with 100^1 of a 50/50 mix of native and heat denatured 
p50 in PBS intravenously (into the tail vein). 4 days later 
2 of the mice were sacrificed and their spleens removed for 
the fusion,
b. Fusion
Spleen cells were removed and washed, red blood cells-were 
lysed by addition of 8% NH^Cl for 10 minutes, then fused 
with the myeloma cell line SP2/0 using polyethylene glycol 
(PEG,SIGMA) at 37°C. Both cell types were in serum-free 
medium and were fused at a ratio of 1 myeloma : 3 spleen. 
After fusion, the cells were plated out at various dilutions 
(neat, 1:5, 1:25) in Dulbecco's modified Eagle's medium 
(D-Mem) containing 50^g/ml streptomycin plus 20%(v/v) foetal 
calf serum (Sera Labs Inc) and 150jug/ml recombinant human 
interleukin 6 (rhIl-6, Boehringer) supplemented with HAT 
(hypoxanthine aminoptorine thymidine [SIGMA]). After 10 days 
this medium was removed and replaced with the same, except 
the HAT supplement was replaced by HT supplement (SIGMA).
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Wells were checked daily both macro and microscopically and 
once cells reached 70% confluence, the medium from the well 
was removed for testing in dot blot assay and replaced with 
fresh medium. If the medium tested positive the cells from 
that well were split into one well of a 24 well plate and 
the medium tested again, once confluence was reached. If 
still positive, the cells were split to give enough for 
freezing and subcloning. Each original well of the 96 well 
plates was tested twice before discarding as negative,
c. Subcloning
Once established in a 24 well plate, positive cultures were 
subcloned using the chequerboard method of dilution. This 
involved transferring' 50jjl of tissue culture medium 
containing hybridoma cells into the top left well of a 96 
well tissue culture plate. This suspension was doubly 
diluted across the rest of the top row of wells in tissue 
culture medium, and then each of these wells was doubly 
diluted down the columns of the plate. Again wells were 
checked daily for the appearance of colonies - any arising 
from a single cell were noted then grown up and the medium 
tested.
Positive clones were again transferred to wells of a 24 well 
plate, a stock was frozen down and the remainder split to be 
grown in tissue culture and to inject into mice to produce 
ascitic fluid.
Once established, the tissue culture cell lines were 
transferred to protein-free hybridoma medium (PFHMll :
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GIBCO) supplemented with rh 11-6 at 50units/ml.
d. Freezing Stocks
Cells to be frozen were pelleted by centrifugation at 
1200rpm for 10 minutes, washed twice in medium then 
resuspended in D-Mem containing 30% FCS and 10% DMSO (SIGMA) 
on ice. Cells were aliquoted into cryovials (Iml/vial) and 
immediately tranferred to -70°C for 24 hours after which 
they were transferred to liquid .
e. Ascitic Fluid
Cells to be injected into mice for ascitic fluid production 
were transferred to serum-free medium, then resuspended in 
PBS and washed once.
The cells were then injected intraperitoneally into Balb/c 
mice which had been primed one week previously with Pristane 
(Sigma). The mice were checked daily for appearance of 
peritoneal swelling, and the ascitic fluid was tapped when 
the mice showed any discomfort.
Collected fluid was centrifuged at ISOOrpm for 10 minutes, 
the serum was removed and left overnight at 4°C, then the 
clot removed and 1ml aliquots stored at -70°C. The cells 
were resuspended in 7ml NH^Cl for 15 minutes, then 
centrifuged as above, resuspended in PBS and left to stand 
for 10 minutes, after which the supernatant was removed, 
underlaid with 2ml FCS and centrifuged at 1500rpm for 10 
minutes. The cells were then frozen or cultured at 37°C in 
RPM1/10%FCS.
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9. Dot Blot Assay
Sheets of nitrocellulose membrane (Amersham) were incubated 
with 200pg of protein for 15 minutes at 20°C, and the 
nitrocellulose then blocked with 10%(w/v) non-fat powdered 
milk (Marvel) for 30 minutes again at 20°C. If required, 
membranes could then be stored at 4°C, after addition of
0.1% NaNg. Test sera or tissue culture media was added in
lOpl volumes at appropriate dilution to the wells of a 
Terisaki plate. The antigen-soaked nitrocellulose membrane 
was blotted dry using a sheet of 3mm filter paper (Whatman) 
then placed over the wells of the plate, with a sheet of 
damp filter paper then placed on top of the membrane. A 
clean Teraski plate was inverted onto the filter paper and 
the wells of the two plates lined up to form a sealed 
channel. The 'sandwich' was then clamped at all four sides 
with bulldog clips, and inverted to drop the serum onto the
nitrocellulose, then incubated for 60 minutes at 20°C.
Plates were again inverted, the membrane removed, and washed 
three times in PBS containing 1%(w/v) non-fat milk powder 
(Marvel).
Antibody-protein complexes were detected using lOuCi 
^25i-protein A in PBS for 60 minutes at 20°C and the 
membrane then washed extensively in PBS until the background 
counts dropped to 2-5cps. The membrane was then exposed to 
X-ray film overnight at -70°C.
10. Preparation of Nuclear and Cytoplasmic Cell Extracts.
A549, Hela, or MG63 cells were grown as monolayers in 75cm
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flasks to 90% confluence. The MG63 cells were serum-starved 
overnight before activation. Cells were activated with 
5ng/ml tumour necrosis factor CK (TNRx,SIGMA) for various
times then the TNF-containing medium was poured off
immediately and the cells harvested by scraping into ice 
cold PBS. Cells were pelleted by centrifugation at 1200rpm 
for 10 minutes and washed twice in ice cold PBS then lysed 
on ice. Lysis was done in 400jul of buffer containing SOmM
NaCl, lOmM HEPES pH8.0, SOOmM sucrose,ImM EDTA, 500pM
spermidine, 150|aM spermine, 0.2% Triton X, 200^M 
phenylmethylsulfonyl fluoride (PMSF), 2mM p mercaptoethanol 
and SOj^M Na-p-Tosyl-phenylalanine chloromethyl Ketone (TPCK) 
on ice for 2 minutes followed by centrifugation in a 
microfuge at 6500rpm for 2 minutes and collection of the 
supernatant as cytoplasmic extract. This process was 
repeated and the supernatants from each time point pooled. 
The cell pellet was then washed very gently (rocking the 
tube - no resuspension) in 200-jil of 50mM NaCl, lOmM HEPES 
pH8.0, 25% glycerol, lOOjiM EDTA, 500pM spermidine, 150joM
spermine, 200jjM PMSF, 2mM p mercaptoethanol and 50jaM TPCK 
three times, and the nuclei then lysed on ice for 60 minutes 
with agitation in 80pl of 350mM NaCl, lOmM HEPES (pHS.O), 
25% glycerol, lOQ^M EDTA, 500juM spermidine, 150yuM spermine, 
200pM PMSF, 2mM jB- mercaptoethanol, and 50^M TPKC. The cell 
debris was removed by centrifugation in a microfuge at 
13,000rpm, and the supernatant removed as nuclear extract. 
The method of Bradford (1970) was used to determine the
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protein concentration of the extracts,
11. Production of Photographs
Negatives were produced from autoradiographs by Bill Blythe 
(Department of Cell and Molecular Biology, University of St. 
Andrews.) and then photographs made. The negative was put in 
an enlarger and focussed onto photographic paper. This was 
exposed for 3 - 5 seconds, put into developer for 1 minute
(or until a clear image was obtained) then fixed for 5 
minutes and finally washed under running water for 2 0 
minutes. The prints were left to dry in a safety cabinet. 
For the immunofluorescence experiments negatives and 
photographs were produced by Bill Blythe.
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RESULTS
Characterisation of Monoclonal Antibodies against p50
The first attempt to produce monoclonal antibodies against 
p50 was unsuccessful, since none of the clones tested 
reacted with p50 in a Western blot. Fifteen different 
clones were tested with the positive control, a polyclonal 
rabbit antisera against p50, giving a strong reaction but 
the others giving no reaction at all. The clones had all 
previously tested positive in a dot blot against native p50 
using an anti—  mouse immunoglobulin but failed to detect 
denatured p50 using the same detection system. Isotyping of 
the clones showed them all to be IgM. Since one of the major 
uses of the monoclones would be to detect proteins in 
Western blots it was decided to try the fusion again.
Figure 5 shows the results of dot blots performed to-test
the tail bleeds from the mice immunised with a mix of
denatured and native p50. Bleeds from mice number 1, 2, 8, 
and 10 all reacted strongly with denatured p50 (Figure 5a) 
as did the polyclonal rabbit antisera. Against native p50 
(Figure 5b) the same sera gave a positive, but slightly
weaker response with the control polyclonal sera again
giving a positive result. No reaction was seen against the 
control protein, BSA, The sera from the tail bleeds was then 
tested in a Western blot against the insect cell line (SF9) 
infected with Baculovirus expressing the p50 precursor pl05. 
As shown in Figure 6, it was again the sera from mice 1, 2, 
8, and 10 that gave a positive result, with no reaction seen
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against uninfected SF9 cells. From these results, mice 1, 
2, 8, and 10 were given a further tail vein boost as
described in the Methods section.
Following the fusion of spleen and myeloma cells, and
selection of fused cells using HAT medium, (see Methods), 
the wells were checked daily for cell growth, and medium 
tested when cells reached 70% confluence. Testing was done 
by dot blot with the medium being tested in 3 blots - one 
against native p50, another against denatured p50 and 
finally against BSA, a control to check for non-specific 
binding. Figure 7 shows the result of one such dot blot 
which identified one positive culture out of the thirty six 
tested to be positive against both native and denatured p50, 
with no reaction against BSA. A total of 12 positive 
cultures were identified in this way and medium was.then 
tested in a Western blot against SF9 cells infected with 
Baculovirus expressing pl05 and uninfected SF9 cells. Figure 
8a shows the results obtained with three of these culture 
media, with 3B6 giving a positive reaction, lane 1, both 6F2
and 8B5 not giving any reaction, lanes 2 and 3 respectively,
and the positive control rabbit polyclonal serum giving a 
positive result as expected. None reacts with the control 
uninfected SF9 cells, suggesting the result to be specific. 
Both 6F2 and 8B5 only reacted with native p50 on a dot blot, 
so this result serves to confirm their non reaction with 
denatured protein and confirms the recognition of denatured 
protein by 3B6. As in previous results, the band detected is
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lower than that expected for pl05, suggesting that 
proteolysis has occurred to produce p50.
All the positive cultures were then subcloned but problems 
were encountered at this stage . Medium from wells 
containing cultures which had grown up from a single cell 
was tested in dot blots as before (data not shown). From 5 
subclones grown up from 3B6, only 3B6A and 3B6B gave a 
positive result with both recognising native and denatured 
p50. None of the other eleven cultures subcloned gave rise 
to antibody producing clones, with some failing to grow 
altogether. This does occur with hybridoma cells which tend 
to shed chromosomes as they replicate to reduce their 
chromosome number. Thus they may lose genes essential for 
growth, or they may lose genes encoding the antibody. The 
two subclones obtained from 3B6 were the only monoclones 
obtained from the second fusion — and were injected into 
mice to produce ascitic fluid, and grown up in tissue 
culture to produce antibody containing medium and stocks of 
cells to freeze down. The ascitic fluid production was not a 
success since the mice formed solid tumours and had to be 
destroyed. However, the tissue culture cells grew 
successfully, and it was decided not to pursue ascitic fluid 
production further, as it was not deemed to be necessary. 
Samples of medium from cultures of both 3B6A and B were 
tested regularly by Western blot against purified p50. An 
example of such a blot is shown in Figure 8b - with lanes 
1-8 blotted with medium from 3B6A cultures at various times
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after splitting, and lanes 9-16 with medium from 3B6B 
cultures. All of the samples tested positive at all times 
tested and were then tested at various dilutions against SF9 
cells infected with Baculovirus expressing pl05. Figure 9 
shows the dilution of 3B6A (lanes 2-8) and 3B6B (lanes 
9-15). The band seen in lane 1 is probably due to leakage of 
antibody out of the manifold used in the blot. The activity 
of the antibody is seen to dilute out down the doubling 
dilution series, with 3B6A giving a stronger result 
throughout. This is probably due to variation in the cell 
numbers and medium volume between the two cultures.
An ELISA was performed to determine the strength of reaction 
of the antibodies against native p50 and the control protein 
BSA. Similar results were obtained with medium from both 
antibodies, and the results obtained with 3B6A are 
summarised in Figure 10. Both antibodies reacted strongly 
with p50 and gave no reaction against BSA. Following this 
result, the 3B6 antibodies were used in immunofluorescence 
experiments on both A549 and Hela cells either inactivated 
or activated with PMA and PHA or TNF-oc. Both antibodies 
failed to detect anything in any experiments carried out 
(data not shown) - suggesting that the epitope recognised by 
the antibodies in vitro was not accessible in vivo. Finally 
on these preliminary characterisation experiments both 
antibodies were isotyped and identified as IgGl.
All the results obtained up to this stage are identical with 
both antibodies, suggesting that they may be very similar,
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if not the same. Functionally, they do not show any 
difference in behaviour at all, and are likely to be 
indistinguishable.
Mapping of the epitope of 3B6A and B.
The recognition of both native and denatured p50 by the 
monoclonal antibodies suggested that they reacted with a 
linear rather than conformational epitope. To try to 
identify the epitope on p50 recognised by the antibody, 
trypsin was used to digest p50. This digestion generated two 
products which could be separated by SDS-Page and visualised 
by staining with Coomassie Brilliant Blue, as shown in 
Figure 11a. The result seen when digested p50 was Western 
blotted with 3B6A is shown in Figure 11b. Neither of the 
trypsin digestion products was recognised by the antibody 
but a strong reaction with the uncleaved p50 was obtained. 
The site of trypsin cleavage of p50 had been determined 
previously in our laboratory (107) and lies within the NLS 
of p50, shown in Figure lie. The same results were obtained 
with 3B6B, and thus show that at least part of the epitope 
recognised by the mAbs is found within the NLS of p50.
The next approach to further define the region on p50 which 
binds the mAbs was to synthesise two peptides ; a lOmer 
which starts at the beginning of the NLS (amino acid 362) 
just upstream of trypsin cleavage site and a 20mer which 
extends from amino acid 352, further upstream of the NLS and 
trypsin cleavage site. The sequences and localisation of the 
peptides are shown in Figure 12a. The mAbs were incubated
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with the peptides before being used in a Western blot with 
p50. Incubation of the mAbs with the 2 0mer peptide blocked 
binding of 3B6A to p50 while the lOmer had no effect as
shown in figure 12b, with the same result seen with 3B6B
(Figure 14c). Even at a concentration of 0.05mg/ml the 20mer 
inhibited binding of p50 by more than 50% while the lOmer 
had no effect even at concentrations of Img/ml. These
results indicate that the binding site of the mAbs on p50 is
located between amino acids 352-371, and includes the 
trypsin cleavage site at residue 362. Since the epitope for 
the antibody binding seems to include the NLS of p50, a 
Western blot was performed using 3B6A on p50 and a protein 
including the NLS of p65. As can be seen in Figure 12c there 
is no cross reaction between 3B6A and p65.
Production of Polyclonal Antisera.
Polyclonal antisera have been raised against many proteins 
and peptides of the rel and ankyrin family of proteins by 
immunisation of rabbits or guinea pigs. In rabbits, antisera 
against p50, p65, ppank (a protein corresponding to 7
ankyrin repeats of pl05) and MAD-3 have been produced as 
well as antisera against N and C terminal of pl05, N and C 
terminal of I-kB, and the C terminal of rel. The sequences 
of these peptides are shown in Figure 13. Most peptides 
alone are not large enough to elicit an immune response and 
so these peptides were coupled through a C terminal cysteine 
residue to the linker SPDP, and then to a carrier protein - 
HSA. A guinea pig was also immunised with MAD-3. Test bleeds
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from the rabbits and guinea pig were taken and tested by 
ELISA. The results from some of these ELISA's are shown in 
Figure 14. As shown, the p50 antibody titre from each rabbit 
(P & M) is good and it stayed like this until the final
bleed - bleed 17. The peptide antisera typically show a high
response to the carrier protein but usually also a good
response to the peptide too. With the C terminal pl05
peptide, this is seen in sera from both rabbits (E & F) with
> ' ino cross reaction with the N terminal peptide. However the N
terminal peptide antisera from both rabbits (T & V) reacts
well with HSA, but shows no reaction with the peptide. The
epitope recognised by antisera against this peptide must be
blocked in the ELISA since the anti - N terminal sera
detected p50 in a Western blot Figure 15b). The N terminal
peptide contains a Lysine residue which may bind to the
gluteraldehyde used to coat the ELISA plate - this residue
may constitute part of the epitope recognised by the sera,
and so be inaccessible for Ab binding in the ELISA. The
varying activity of sera collected at different times is
shown in Figure 14d, This shows a marked increase in
activity at bleed 2 while the response in rabbit D is much
higher in bleed 3 than any other. Rabbit G shows a much more
typical profile - with the titre being maintained in later
bleeds. All the antisera that have been produced and tested
to date have given strong reactions with the protein used
for immunisation (data not shown).
Some of the antisera produced have been used further to
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elucidate the subcellular localisation of different subunits 
of NF-kB and I-kB in unactivated and activated cells. 
Localisation of pl05.
Early experiments made use of the antisera raised against 
the N and C terminal peptides of pl05. Western blots using 
nuclear and cytoplasmic extracts of Jurkat cells before and 
after activation with PMA and PHA were probed with these 
peptide antisera. Figure 15a shows the C terminal peptide 
antisera detects a band in cytoplasmic extracts of 
unactivated cells but nothing in cytoplasmic extracts of 
activated cells or in nuclear extracts of unactivated or 
activated cells, although there is a mark on the blot in the 
activated nuclear extract lane. However, the edges and 
corners of the blot often show some marking due to handling 
of the nitrocellulose membrane with tweezers. Since it is 
generally accepted that pl05 is not found in the nucleus of 
activated cells and the mark is more like two dots than a 
band, this would seem the most likely explanation. This band 
corresponds to pl05 - as seen by its size and the expected 
distribution. The N terminal peptide serum detects a smaller 
size band, generated by proteolytic cleavage of pl05 - this 
is p50 (Figure 15b). Blocking of the sera by incubation with 
the corresponding peptide abolished recognition by the 
antisera.
Immunofluorescence experiments were also carried out using 
the peptide antisera, but the results obtained were not 
consistent and so were difficult to interpret. The results
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are not shown since they did not photograph clearly .
Further Characterisation of Antisera.
More Western blots were performed using nuclear and 
cytoplasmic extracts from PMA-activated Jurkat cells probed 
with the polyclonal p50 antibody (data not shown). This 
antibody detects a range of bands with the strongest in the 
activated nuclear extracts and corresponding to about 50kD 
size. This band is also seen in the cytoplasm where it is 
less intense. There are also higher molecular weight' bands 
corresponding to pl05 seen in the cytoplasm and decreasing 
in intensity following activation.
Western blots were then done with the I-kB-GST fusion 
protein or purified I-kB. The blots were probed with 
preimmune sera, polyclonal I-kB rabbit sera, and polyclonal 
sera from both the guinea pig bleeds. The blot results are 
shown in Figure 16. The preimmune sera do not detect 
anything in either blot, while all three polyclonal sera 
pick up 3 bands against the fusion protein, and only the 
smallest band in the I-kB blot. The smallest band is likely 
to be I-kB, while the larger bands in the fusion protein 
blot will be fusion protein and GST.
Localisation of p50 and I-kB
To increase the specificity of reaction and decrease 
background reactions, the polyclonal antisera against p50, 
I-kB, and p65 were affinity purified. Since I-kB was 
produced as a fusion protein with GST, the Ab was purified 
first over a GST column, then a Hitrap I-kB column. The
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purification was tested by dot blot since I-kB does not bind 
well to Coomassie and so cannot be assayed by the method of 
Bradford. The results of the purification were good with the 
Ab eluting in fractions 1-8 (Figure 17). The other antisera 
- against p50 and p65 - were purified by J Bosher and F 
Arenzana-Seisdedos in our laboratory.
Work on refining the protocol for preparation of nuclear and 
cytoplasmic extracts was performed in our laboratory by F 
Arenzana-Seisdedos and R T Hay (Department of Cell and 
Molecular Biology, University of St. Andrews.). This 
protocol was then used to prepare nuclear and cytoplasmic 
extracts from A549, Hela, and MG63 cells to be used in 
Western blots to determine the localisation of I-kB and 
pl05/p50 at different times after activation with TNFx. 
Firstly, a Western blot was performed using p50 Ab to 
determine efficiency of the new extraction protocol. As 
shown in Figure 18a, pl05 is observed in the cytoplasmic 
extracts of MG63 cells at all times after activation, while 
p50, but not pl05, was present in the nuclear extracts - 
suggesting no contamination of nuclear extracts by 
cytoplasm.
Blots were then performed on the three different cell types 
using the purified p50 and I-kB polyclonal antisera. In A549 
cells, I-kB was shown to be present in the nucleus before 
TNF activation but no longer there 30 minutes later with a 
faint band seen at 2 hours after activation (Figure I9a). In 
cytoplasmic extracts, I-kB was seen before activation but
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had disappeared at 30 minutes and 1 hour after activation, 
reappearing at 2 hours post activation (Figure 19b). In both 
Figure 19a and b, no reaction is seen with the purified I-kB 
Ab against lOng GST, and lOng Bcl-3, with very strong 
activity against lOng I-kB and one clear band seen against 
Ing I-kB. This shows the specificity and purity of the Ab.
In MG63 cells, no nuclear I-kB was detected - only a 
non-specific band which is often observed (Figure 20 lanes 
1-5), but in the cytoplasm, I-kB is seen before activation 
(Figure 20 lane 6), very faintly after 5 minutes activation 
(lane 7) and 2 hours after activation (lane 10). As shown in 
Figure 18, the levels of p50 increased in the nucleus 5 
minutes after activation and stayed at an elevated level 
through 15 and 45 minutes after activation, decreasing back 
to that seen before activation by 2 hours. In. the 
cytoplasmic extracts, a slight decrease in pl05 levels was 
seen after TNF activation returning to basal level by 2 
hours after activation. Very little change was observed in 
cytoplasmic p50 levels.
Finally, Western blot analysis of Hela cell nuclear extracts 
again showed a decrease in nuclear I-kB 10 minutes after TNF 
activation, with no I-kB seen 50 minutes after activation 
and a reappearance beginning at 2 hours post-activation 
(Figure 21a lanes 1-4), An increase in nuclear p50 is 
observed 10 minutes after TNF activation and this is 
maintained throughout (Figure 21b lanes 1-4), The 
corresponding blot on cytoplasmic extracts showed no
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degradation of cytoplasmic I-kB and showed no change in p50 
levels (Figure 21b lanes 5-8). However, on testing the batch 
of TNF used for activity, very low levels of activity were 
found, so the experiment was repeated using extracts 
activated with a new batch of TNHX. The results of this blot 
on extracts activated for 0 minutes, 50 minutes and 2 hours 
are shown in Figure 21c. These results show a low level of 
I-kB present before activation, with none seen after 50 
minutes and reappearance after 2 hours.
In all of these experiments a higher molecular weight band 
(about 80kD) is often detected by the I-kB antisera - this 
has been observed consistently by many workers in the 
laboratory, and is likely due to cross-reaction with another 
protein. However, the fact that this band shows an inverse 
relationship with the I-kB band suggests that I-kB itself 
may form part of a complex which is detected by this 
antibody. After prolonged cell activation this complex 
breaks up and releases the I-kB. The p50 Ab detects p50 as a 
doublet, which decreases slightly in size immediately after 
activation.
Since the presence of I-kB in the nucleus of cells remains a 
controversial issue, further studies were performed by 
immunofluorescence on Hela and MG63 cells at different times 
following TNBx activation. The time course used for each 
cell type was the same as that used for the corresponding 
cell type in the Western blots.
In MG63 cells a broad distribution of I-kB in both nucleus
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and cytoplasm of cells before activation by TNPüc (Figure 
22a). At 5 and 15 minutes after activation there is no 
staining of cells in either nucleus or cytoplasm (Figure 22b 
and c) but I-kB reappears in cells at 45 minutes and 2 hours 
after activation, again staining in both nucleus and 
cytoplasm (Figure 22d and e). In Hela cells however, there 
is no detectable change throughout the time course of 
activation (Figure 23a,c,e,g) with I-kB maintaining a 
nuclear and cytoplasmic distribution throughout. The 
corresponding time course of activation using preimmune 
rabbit serum is shown in Figure 23(b,d,f,h) - very little 
staining is observed in these cells, suggesting the staining 
seen using the I-kB antibody is specific. Hela cells stained 
with p50 antibody are shown in Figure 24(a-d). A shift from 
general cell staining with more cytoplasmic p50/pl05 to 
predominantly nuclear staining in TNRx activated cells is 
seen, with a return to more overall cell staining by 50 
minutes and 2 hours, although the cytoplasmic staining is 
still not as pronounced as before activation. The lack of 
staining seen with pre-immune serum is shown in Figure 24 e 
and f . In Hela cells the effect of TNF seemed minimal, with 
no major differences seen in the staining pattern of the 
proteins. This illustrates the difficulties that can be 
encountered in trying to detect relatively low levels of 
cellular proteins with polyclonal antisera and also explains 
the lack of published immunofluorescence data except in 
transfected cells. Much time was put into trying to optimise
-  62 -
the fluorescence procedure and following a few further 
modifications a clear data set should be obtained on Hela 
cells as well as the MG63 cells.
In some of the immunofluorescence experiments the staining 
of the protein is diffuse while in others a more speckled 
pattern is seen. It could be that the more speckled staining 
illustrates proteins localised to distinct subcellular 
sites. The nonspeckled staining may be due to diffusion of 
proteins to or from these specific sites' in response to 
activation signals. Further work will be required to 
elucidate the nature of these protein pockets.
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DISCUSSION
Using the polyclonal antisera against p50 and I-kB it has 
been possible to demonstrate the subcellular localisation of 
these proteins. As has been shown previously, indirect 
immunofluorescence studies illustrate that on activation of 
cells with PMA, p50 moves from predominantly cytoplasmic to 
a predominantly nuclear staining.
Antibodies to the MAD-3/I-kBcx protein show that this 
inhibitor can be located in both the nucleus and cytoplasm 
of cells. The results obtained in fluorescence correlate 
with other observations (48) from transfection experiments 
that show MAD-3 can be located in the nucleus of cells. It 
is hot clear whether MAD-3 has its own NLS or passively 
enters the nucleus due to its size of only 37kD (37) but the 
presence of the inhibitor in the nucleus is not particularly 
surprising. There it could facilitate the inactivation of 
NF-kB released from DNA or could actively remove NF-kB from 
DNA, thus halting transcription induced by NF-kB which 
otherwise could continue uncontrolled. This potential role 
for I-kBoc is supported by an early observation that 
inactivation and redistribution of NF-kB from nucleus to 
cytoplasm 8 hours after phorbol ester stimulation was 
inhibited by cycloheximide - which suggests the involvement 
of a newly synthesised protein. As p65 has since been shown 
to induce I-kBx mRNA expression, extracellular stimulation 
of cells does lead to production of I-kBx about 2 hours 
after stimulation.
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The data seen in Western blots carried out on TNRx activated 
cells confirm that nuclear I-kB is seen before activation, 
then disappears and reappears about 2 hours after 
stimulation. Degradation of I-kB in both nucleus and 
cytoplasm was seen in all cell lines tested, both here and 
in other experiments carried out in our laboratory, 
following activation, reappearing some time after 
activation. However, in immunofluorescence experiments 
different results were seen in Hela cells and MG63 cells, 
with disappearance of I-kB following activation only 
detected in MG63 cells.
In MG63 cells, the time points examined are 5, 15 and 45 
minutes post-activation, with the MAD-3 reappearing by 45 
minutes. Further refining of the immunofluorescence protocol 
may also be required, and the condition of the cells when 
the fixing, permeabilisation, and staining is done may prove 
critical to the result. The experiment shown on MG63 cells 
used cells activated that same day, whereas the Hela cells 
were stored overnight at 4°C after fixing, although this is 
unlikely to make protein * reappear’I The MAD-3 in Hela cells 
after activation is maintained in the cytoplasm - as seen in 
Western blots - and may leech back into the nucleus 
following fixation, especially if the cells are stored at 
4^C for a length of time. The nucleus does stain deceptively 
strongly due to its depth on the coverslips. Cytoplasm is 
spread out thinly on the glass but the nuclei remain in 
their rounded form and so give a much stronger staining.
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Therefore a relatively small amount of MAD-3 (or any 
protein) leeching from cytoplasm to nucleus would give quite 
a visible staining. However, formaldehyde fixation should be 
sufficient to prevent this. Fluorescence studies on cells 
transfected with MAD-3 have shown the protein to be present 
in the nucleus of cells (48) but the system used 
over-expressed proteins and so may not be an accurate 
reflection of the in vivo situation. The presence of 
residual MAD-3 in the nucleus has recently been shown in 
cells treated with TNFx in the presence of TLCK (a serine 
protease inhibitor) (108). In these cells nuclear 
translocation of p50 is not completely blocked but there is 
no detectable DNA binding activity. This residual MAD-3 may 
not be sufficient to give the observed staining in Hela 
cells - but could contribute to the leeching MAD-3 - such 
that small amounts of MAD-3 which may not be detectable in 
their own right may add together to give a detectable 
level.
Demonstration of p50 and I-kB in the nucleus of cells before 
activation, and the subsequent disappearance of I-kB with 
p50 remaining, would give the best evidence for I-kB in the 
nucleus. This is difficult to show due to the lack of any 
pattern to the staining in the nucleus. The use of laser 
scanning confocal microscopy may aid this investigation 
since it 'slices* the nucleus so that single layers can be 
examined, as has been shown for p50. The guinea pig I-kB Ab 
and rabbit p50 Ab could be used to enable differential
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staining of the two proteins.
The production of monoclonal antibodies againt p50 has for 
some reason proved very difficult. Attempts by many 
laboratories have proved fruitless while the yield of 
productive clones from successful fusions has been very low. 
The method described in Chapter Two was modified from a 
first unsuccessful attempt and incorporated several changes. 
First time round, mice were injected with native p50 only - 
not a mixture of native and denatured protein. The detection 
method was changed from ELISA using anti mouse 
immunoglobulin - thereby detecting all classes of antibody 
produced against native p50 - to two dot blots (one against 
native, the other denatured p50) detected by [ I]-Protein 
A, which only detects IgG antibodies. The reasoning behind 
the changes was simple ; the ELISA used originally was not 
sensitive enough, with very little difference in readings 
between background and positive values and it required at 
least 50pl of tissue culture medium. The dot blot is 
quicker, much more sensitive, and allows testing against 
both native and denatured protein. The injection of a 
mixture of native and denatured protein was used to produce 
antibodies which would be useful for Western blotting 
since the first fusion using native p50 only - did not 
produce any clones reactive against denatured p50. All the 
positive clones from the first fusion were found to be IgM, 
and so proved difficult to use - giving very poor detection 
levels in ELISA and immunofluorescence - so it was decided
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to use -Protein A to identify positive clones in the
second fusion, so that only antibodies of IgG subclass would 
be selected.
Finally, from two fusions and many subclonings, a positive 
monoclonal antibody was obtained and grown up in bulk in 
serum-free medium (to maintain purity and remove need for 
purification). The original dot blot screening showed it to 
recognise both native and denatured p50 and it picks up a 
single band corresponding to p50 when used in Western blots. 
However, it failed to detect anything in immunofluorescence 
experiments, suggesting that in vivo its epitope on the 
protein might be masked. Since the antibody could recognise 
both native and denatured protein, the epitope was likely to 
be linear and in Western blots only recognised p50, not 
pl05. Recognition of p50 but not BSA in ELISA confirms that 
the antibody specifically recognises native p50. The results 
of the cleavage experiments using trypsin on p50 narrowed 
down the location of the antibody binding site and 
competition experiments with synthesised peptides showed 
that the antibody binds to a region within the NLS of p50. 
Further studies (109) illustrated that binding of the mAb 
3B6-A to p50 is blocked by addition of a protein mentioned 
briefly before, consisting of seven ankyrin repeats, and by 
the C terminal region of pl05 - confirming the result seen 
in Western blots of insect cells expressing pl05.
The monoclonal antibody 3B6-A has already proved to be 
useful in identifying proteins which bind to the NLS of p50.
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Already other studies in our laboratory (109) have shown 
that 3B6A does not inhibit DNA binding of p50 - confirming
that the NLS is not involved. No cross reaction is seen
between 3B6A and p65, suggesting the monoclone recognises a 
unique epitope on p50. This should also prove useful since 
the high degree of homology between rel family proteins 
always means the possibility of cross reactions. 
Unfortunately, the monoclone does not detect protein in 
immunofluorescence studies. This is to be expected in the 
cytoplasm since the NLS is masked, presumably by the c 
terminal of pl05. However it also suggests masking of the 
epitope once p50 has been translocated to the nucleus. The 
next problem is to identify the protein which masks the 
epitope. It is very unlikely to be p65, since 3B6A will 
immunoprecipitate a heterodimer of p50-p65. Again, MAD-3 
could be a candidate given that it is detected in the
nucleus of cells, and that it does partially protect the NLS 
of p50 from trypsin cleavage. However, the monoclone cannot 
immunoprecipitate complexes of MAD-3 and p50 (109). Further 
investigation is required into the interactions of p50 with 
other proteins once it is translocated to the nucleus. It 
had been hoped that a panel of monoclones recognising
different regions of p50 would be obtained to help elucidate 
further the areas involved in interaction with other 
proteins - unfortunately this was not accomplished. The non 
reactivity of the antibody in immunofluorescence is 
frustrating since it could have been used in double
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labelling experiments to attempt to determine the relative 
localisation of p50 and MAD-3. However a guinea pig 
polyclonal antiserum has been raised against MAD-3, so 
perhaps studies with this in the future will further 
elucidate the interaction between these two proteins, since 
the rabbit p50 Ab and guinea pig I-kB Ab could be detected 
by different fluorochromes.
Many other antisera have been raised - but not as yet put to 
much use. These include antibodies against p65, the partial 
ankyrin protein (seven ankyrin repeats), and peptide 
antisera to the N and C termini of I-kB and pl05. The 
polyclonal p65 antiserum has been used extensively by 
F. Arenzana-Seisdedos and R. T. Hay. For each protein or 
peptide, two rabbits were immunised and in most cases both 
produced serum which reacted strongly with the immunogen. 
However, with p65 only one rabbit gave reactive serum and 
only one bleed from this rabbit was of good reactivity. 
Usually the titre of the antibody (as measured in ELISA) 
increased at each bleed then plateaued off, at which time 
the rabbits were sacrificed and bled out. Some rabbits 
continued to produce high titre sera until about bleed 17 
(p50), and the sera increased in affinity as the immune 
response continued to select for high affinity clones.The 
case with p65 was surprising and the reason behind it not 
clear unless the protein injected became less pure such that 
the response was raised against a wider range of epitopes. 
The production of peptide antisera was successful to a large
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extent, although the sera have to be purified due to the 
large response elicited against the carrier proteins. 
Because of the need for careful purification, and the range 
of cross reactions which may occur, the peptide antisera 
have as yet not been used routinely with the exception of 
the N and C terminal pl05 sera. These were used early on in 
the project in both Western blots and immunofluorescence to 
determine the subcellular localisation of p50 and pl05. 
Surprisingly, it was observed that following cell activation 
pl05 was detected in the nucleus of Jurkat cells, but using 
an improved extraction procedure this was no longer 
observed, with pl05 only detected in cytoplasmic extracts, 
therefore the original detection was probably due to 
contamination of nuclear extracts with cytoplasm. It is 
still controversial as to whether pl05 can enter the nucleus 
of activated cells although it has been detected in the 
nuclei of unactivated cells. A complex formed with the
HTLV-1 Tax protein (in its active form) and pl05 has been
shown to translocate into the nucleus (110), and in Jurkat
cells a complex between hc-Rel and pl05 is also found in the 
nucleus (111). However, immunofluorescence studies on a 
GAL4-pl05 fusion protein transfected in CEF cells showed the 
pl05 fusion protein to have a cytoplasmic localisation 
(112). The first two studies reflect a more in vivo
situation, but there is considerable variation in results 
from different groups using different cell types. It would 
seem that pl05 maintains a cytoplasmic localisation unless
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in complex with another protein which may result in a 
conformational change to unmask its NLS, or to provide 
another NLS. It does seem possible that pl05 can enter the 
nucleus of cells : recent evidence that MAD-3, one of the 
I-kB family, can be located in the nucleus would lend 
support to this, since the C terminal of pl05 encodes on 
I-kB protein.
It is hoped that the work described in this thesis will 
contribute to the elucidation of the role of NF-kB and I-kB 
proteins in cellular activation, and that a further 
understanding of these events will aid work towards the 
prevention and / or treatment of diseases such as viral 
infection and cancer.
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Figure 5
Dot blot showing the reactivity of sera from tail bleeds of 
mice immunised with a mix of native and denatured p50. 
Sheets of nitrocellulose paper were incubated with native or 
denatured p50 then serum was applied as described in 
Methods. Bound antibodies were detected by ^^^I-Protein A 
and autoradiography. Activity against denatured p50 is shown 
in A, against native p50 in B, and against BSA as a control 
in C.
The layout of the sera on the blot is as follows
10 +ve C
+ve C is rabbit polyclonal anti-p50 Ab
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Figure 6
Western blot showing the reactivities of sera from tail 
bleeds of mice immunised with a mixture of native and 
denatured p50. SF9 cells infected with Baculovirus 
expressing pl05 or control cells infected with non­
transfected Baculovirus were separated by SDS-PAGE and 
electrophoretically transferred to nitrocellulose membrane. 
Bound antibodies were detected by ^^^I-Protein A and 
autoradiography. The number above each lane corresponds to 
the number of the mouse from which the serum was taken, with 
the sera used at ^/2qo dilution. The blot with SF9 cells 
expressing pl05 is shown in A - with sera 1, 2, 8, and 10
giving a positive reaction to a p50 size band while B shows 
none of the sera react with SF9 cells not expressing pl05.
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Figure 7
Testing of hybridoma culture medium by dot blot against 
native or denatured p50 or BSA. Blot was performed as 
described previously (Figure 5). Panel A shows the result 
using denatured p50, panel B native p50, and panel C BSA. 
One positive is seen in both A and B - this is the same 
hybridoma in both - 3B6. No reaction is seen with BSA.
Layout of the blot is as follows
3B6 8B5 6F2
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Figure 8
A. Western blot of culture medium from hybridomas tested 
positive in dot blot. Blot performed as in Figure 6 with 
Baculovirus infected SF9 cells expressing (Panel A), or 
not expressing (Panel B), pl05. The medium tested is 
from hybridoma 3B6 (lane 1), 6F2 (lane 2), 8B5 (lane 3), 
and anti-p50 rabbit polyclonal antisera is used in lane
4 as a positive control. Only 3B6 and the control Ab 
give a positive reaction - none reacts with the control 
cells which do not contain pl05.
B. Western blot with p50 run on SDS-PAGE then transferred 
to nitrocellulose membrane. Detection is by ECL 
(chemiluminescence system) for a 30 second exposure.
The blot is probed with tissue culture medium from
various 3B6A cultures: 1 (lane 1), 2 (lane ), 5 (lane
3), 7 (lane 4), 8 (lane 5), 12 (lane 6), 16 (lane 7),and 
20 (lane 8) : or 3B6B cultures : 2 (lane 9), 4 (lane
10), 8 (lane 11), 11 (lane 12)., 14 (lane 13), 20 (lane
14), 21 (lane 15), and 23 (lane 16).
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Figure 9
Western blot of Bacterially expressed p50 separated by 
SDS-PAGE and electrophoretically transferred to 
nitrocellulose membrane. Detection is by ECL for 1 minute 
exposure. Both antibodies 3B6A and 3B6B are used in a series 
of doubling dilutions from 1 in 2 to 1 in 128 with 3B6A in 
lanes 2-8, and 3B6B in lanes 9-15.
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Figure 10
Graph showing results of an ELISA to determine the level of 
binding of 3B6A to p50. 3B6A culture medium was added in 
doubling dilutions to wells of a 96 well plate coated with 
native p50. Bound antibody was detected by anti-mouse IgG 
and TMB substrate. Each point on the graph represents the 
average of 4 OD readings obtained for each dilution at 
630nm. The first point represents neat tissue culture 
medium, and the last is Vio24
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Figure 11.
Purified p50 was mixed with trypsin at various ratios for 3 
hours then the reaction stopped by addition of PMSF to IMm. 
The products of digestion were separated by SDS-PAGE then 
stained with Coomassie Brilliant Blue (A) or Western blotted 
with 3B6A (B). The ratio of p50 ; trypsin (w:w) in both is 
as follows: 0 (lane 1), 2000 (lane 2), 1000 (lane 3), 500
(lane 4), 200 (lane 5). Panel C shows the site of trypsin
cleavage on the NLS.
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Figure 12.
A. Sequence of the p50 NLS, the site of the trypsin 
cleavage, and the composition of the lOmer and 20mer 
peptides.
B. 3B6A was mixed with varying amounts of lOmer and 20mer 
peptide and then used to probe for p50 on a Western blot. 
Lanes 2-7 show incubation with the lOmer at 
concentrations of 0, 0.05, 0.1, 0.2, 0.5, and l.Omg/ml 
respectively, while lanes 10-15 show incubation with the 
20mer at the same range of concentrations.
C. Lane 1. Western blot of p50 probed with 3B6A and detected
by ECL for a 1 minute exposure.
Lane 2. Western blot of p65 probed with 3B6A detected as 
Lane 1.
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Figure 13
Sequences of synthetic peptides used in production of 
polyclonal antisera. A - N terminal pl05. B - C terminal 
pl05. C - C terminal p65 rel. D - N terminal I-kB. E - C 
terminal I-kB. All have a terminal cysteine residue to 
enable coupling to the linker molecule.
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FIGURE 13
N term pl05 peptide
M A
C term pl05 peptide
C term p65 rel
N term I-kB peptide (MAD-3)
C term I-kB peptide (MAD-3)
Figure 14
Graphs showing results of ELISA*s to test the reactivity of 
protein/peptide polyclonal antisera, against the immunogen 
and control peptides/proteins. Blots C and D are shown on 
the next page.
A. Antisera against C terminal of pl05.
B. Antisera against N terminal of pl05.
C. Antisera against p50 (DBD).
D. Graph showing response over time to p65 - from preimmune
serum to final bleed
In panels A, B, and C the substrate used is OPD and OD is 
measured at 492nm, while in panel D, TMB substrate is used 
and measured at 630nm.
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Figure 15
Western blots with nuclear and cytoplasmic extracts from 
Jurkat cells before and after stimulation with PMA and PHA 
for 30 minutes.
A. Unactivated cytoplasm (lane 1), activated cytoplasm (lane 
2), unactivated nuclear (lane 3), activated nuclear (lane
4). Jurkat extracts probed with rabbit polyclonal anti-C 
terminal peptide antisera. Lanes 5-8 are as lanes 1-4, but 
probed with antibody preincubated with the peptide for 30 
minutes at 37°C.
B. As A but probed with rabbit polyclonal anti-N terminal 
peptide antisera.
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Figure 16.
A. Western blot with I-kB-GST fusion protein.
B. Western blot with I-kB.
Proteins were separated by SDS-PAGE and electrophoretically
125transferred to nitrocellulose. Detection was by I-Protein
A. Blots were probed with polyclonal antisera as follows 
preimmune rabbit serum (lane 1), rabbit anti-MAD-3 serum 
(lane 2), guinea pig anti-MAD-3 seruml (lane 3), and guinea 
pig anti-MAD-3 serum2 (lane 4).
Band 1 corresponds to I-kB/GST fusion protein.
Band 2 corresponds to GST.
Band 3 corresponds to I-kB.
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Figure 17.
Dot blot to test fractions from affinity purification of 
antiserum against MAD-3 for anti-MAD-3 activity. 
Nitrocellulose membrane was incubated with MAD-3 then 
samples from various stages of the purification were 
''dotted*' on. Detection of bound Ab was by ECL. Layout of 
the blot is as follows;
row 1 +ve C l  2 3 4
row 2 5 6 7 8 9
row 3 10 11 12 13 14 . 15
row 4 16 17 18 19 20
row 5 ^2A
Numbers represent the elution number off the column (each 
represents a SOjxl fraction) . W is wash cycles with being 
the first wash cycle, and being the second wash cycle. 
is the final wash and is the flow through off the 
column. The positive control (+ve C) is unpurified 
polyclonal anti-MAD-3 Ab.
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Figure 18.
Western blot of MG63 cells at various times after activation 
by TNRx probed with purified anti-p50 Ab. Nuclear and 
cytoplasmic extracts are prepared and separated by SDS-PAGE, 
then transferred electrophoretically to nitrocellulose 
membrane. Detection is by ECL for a 2 minute exposure. Lanes 
1-5 show nuclear extracts at time 0, 5, 15, 45, and 120
minutes respectively after TNRx activation, while lanes 6-9 
show cytoplasmic extracts at time 0, 5, 15 and 45 minutes 
after activation.
The size of the bands was marked at the time against 
prestained molecular weight markers. The markers were too 
faint to photograph and so are not shown for any of the 
blots.
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Figure 19.
Western blot of A549 cells at various times after activation 
by TNPbc probed with purified I-kB Ab performed as above 
(Figure 18) .
A. Nuclear extracts at time 0, 30 and 60 minutes after 
activation (lanes 1-3 respectively). Control proteins 
long GST, lOng I-kB, Ing I-kB, lOng Bcl-3 (lanes 4-7 
respectively).
B. Cytoplasmic extracts at time 0, 30, 60 and 120 minutes 
after activation (Lanes 1-4 respectively). Control 
proteins lOng GST, lOng I-kB, Ing I-kB, lOng Bcl-3 (Lanes 
5-8 respectively.
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Figure 20
Western blot of MG63 cells at various times after activation 
with TNFoc, probed with purified I-kB Ab, Performed as in 
Figure 18. Lanes 1-5 show nuclear extracts at times 0, 5, 
15, 45, and 120 minutes after activation, while lanes 6-10 
show the same time points in cytoplasmic extracts.
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Figure 21.
Western blot of Hela cells at various times after activation 
with TNFx, probed with purified I-kB Ab (Panel A and C), or 
purified p50 Ab (Panel B). In both A and B, lanes 1-4 show 
nuclear extracts at 0, 10, 50, and 120 minutes after
activation respectively and lanes 5-8 show the same time 
points for cytoplasmic extracts.
Panel C shows a Western blot performed on cytoplasmic 
extracts activated using a new batch of TNRx for 0, 50, and 
120 minutes (lanes 1 - 3  respectively).
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Figure 22.
Photographs of MG63 cells at various times after activation. 
After activation with TNRx for the appropriate time, cells 
were fixed with formaldehyde, permeabilised, and labelled 
with purified anti-MAD-3 rabbit polyclonal Ab used at V ^ qoo 
dilution. Bound antibody was visualised by use of FITC 
conjugated anti-rabbit IgG. Cells were examined 
microscopically and photographs taken. Panels A, B, C, D, 
and E show the cells after 0, 5, 15, 45, and 120 minutes
activation respectively.
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Figure 23,
Photographs of Hela cells treated as in Figure 22. Panels A, 
C, E, and G show the cells after 0, 10, 50 and 120 minutes
activation respectively with TNRx, probed with purified I-kB 
Ab used at V j^ q q q dilution. Panels B, D, F, and H show 
corresponding time points, but the cells are labelled with 
preimmune serum.
Here there is no degradation of I-kB seen - maybe this is 
due to the TNF not working since there was very little 
degradation of I-kB seen in the corresponding Western blot 
on these cells (Figure 21a).
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A
Figure 24.
Photographs showing Hela cells prepared as in Figure 22. 
Panels A-D show cells 0, 10, 50, and 120 minutes after
activation, labelled with purified polyclonal rabbit 
anti-p50 Ab used at ^/sq oo dilution. Panels E and F show 
cells at 10 and 120 minutes after activation, labelled with 
preimmune rabbit serum.
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